Rockefeller University

Digital Commons @ RU
Student Theses and Dissertations

2016

Structural and Functional Characterization of
SPOA Domains in Salmonella Typhimurium Type
III Secretion Systems
Ryan Q. Notti

Follow this and additional works at: http://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons
Recommended Citation
Notti, Ryan Q., "Structural and Functional Characterization of SPOA Domains in Salmonella Typhimurium Type III Secretion
Systems" (2016). Student Theses and Dissertations. Paper 313.

This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and
Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact mcsweej@mail.rockefeller.edu.

STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF
SPOA DOMAINS IN SALMONELLA TYPHIMURIUM
TYPE III SECRETION SYSTEMS

A Thesis Presented to the Faculty of
The Rockefeller University
in Partial Fulfillment of the Requirements for
the degree of Doctor of Philosophy

by
Ryan Q. Notti
June 2016

© Copyright by Ryan Q. Notti 2016

STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF SPOA
DOMAINS IN SALMONELLA TYPHIMURIUM TYPE III SECRETION SYSTEMS
Ryan Q. Notti, Ph.D.
The Rockefeller University 2016

Once optimistically believed to be a relic of the pre-antibiotic era, bacterial
pathogens remain a substantial threat to human health, and the growing
epidemic of antibiotic resistance has raised concerns for the long term prospects
of antimicrobial therapy. By understanding the mechanisms used by bacteria to
manipulate their host and cause disease, it is hypothesized that we might more
rationally approach anti-infective therapeutic design.
Type III secretion systems (T3SS) are employed by some gram-negative
human pathogens to manipulate the host environment. One T3SS subtype,
known as the “injectisome,” delivers virulence factors directly into host cells. The
other T3SS subtype secretes the the polymeric flagellar filament used for motility.
While both systems share related elements of a cytoplasmic “sorting platform”
that facilitates the hierarchical secretion of protein substrates, the structural
mechanism of its assembly remains unclear.
The work described in this thesis makes strides towards the mechanistic
understanding of T3SS sorting platform assembly by applying structural,
biochemical, and genetic techniques to the characterization of the SctQ/FliM/FliN
protein family and their interactions with other sorting platform components.
These proteins uniquely possess Surface Presentation Of Antigens (SPOA)
folds, and I will present the molecular structures of distinct homotypic and

heterotypic SPOA-SPOA interactions in the Salmonella typhimurium SPI-1
sorting platform protein SpaO (Chapter 2). In Chapter 3, I structurally
characterize the interaction of the heterotypic SPOA complex with a regulator of
the SPI-1 ATPase and demonstrate the necessity of the interaction for T3SS
secretory function. Then, I will present the homologous structures from the S.
typhimurium flagellar apparatus and compare and contrast them with their SPI-1
homologues, providing an explanation for the observed subtype specificity in
sorting platform assembly (Chapter 4). In Chapter 5, biochemical evidence for an
interaction of the SpaO amino-terminal domain(s) with the homotypic SPOA
complex is presented. These results provide a model for the subtype-specific
assembly of T3SS sorting platforms and will support further mechanistic analysis
and anti-virulence drug design (Chapter 6).
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CHAPTER 1:
INTRODUCTION

Portions of this chapter have been accepted for publication in the forthcoming 5th
edition of “Virulence Mechanisms of Bacterial Pathogens” (ASM Press).

The clinical application of antibacterial small molecules (“antibiotics”) has
revolutionized infectious disease medicine over the past six decades; however,
the rise of antibiotic resistance has generated new challenges in the effective
treatment of bacterial infections (1, 2). The United States Centers for Disease
Control and Prevention estimates that 2 million Americans are infected by
antibiotic resistant bacteria annually, resulting in more than 23,000 deaths (3).
Hypothetically, therapeutic targeting of the machinery responsible for bacterial
virulence in the human host might afford treatment strategies with a lower
likelihood of evolution of resistance and decreased bystander damage to the host
microflora (2, 4). To facilitate the discovery or design of such therapeutics, many
have endeavored to understand the molecular basis for bacterial virulence,
including the bacterial systems responsible for the delivery of toxic biomolecules
from the bacterium to the host.

1.1 Type III secretion systems
Type III secretion systems (T3SS) afford gram-negative bacteria a most intimate
means of altering the biology of their eukaryotic hosts — the direct delivery of
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effector proteins from the bacterial cytoplasm to that of the eukaryote (5, 6).
T3SS utilize a conserved set of homologous gene products to assemble the
nanosyringe “injectisomes” capable of traversing the three lipid membranes,
peptidoglycan layer and extracellular space that form a barrier to the direct
delivery of proteins from bacterium to host. While the injectisome is
architecturally similar across disparate gram-negatives, its applications are a
study in diversity: T3SS are employed by both symbionts and pathogens; they
target animals, plants, and protists; and they are used to manipulate a wide array
of cellular activities and pathways.
T3SS have attracted intense scientific interest since the seminal work
documenting their discovery was published over two decades ago (7-9). Given
their role in the virulence of several human and plant pathogens (e.g. Salmonella
enterica, Shigella flexneri, Yersinia spp., pathogenic Escherichia coli, Vibrio spp.,
Pseudomonas spp., Chlamydia spp.), T3SS are attractive targets for the
discovery or design of novel anti-infective agents and vaccine approaches that
disrupt toxin delivery. Conversely, harnessing T3SS function might also be of
human benefit: as T3SS accomplish the biophysical feat of protein transduction
across multiple membranes, their re-engineering for in vivo delivery of
therapeutic proteins or in vitro production of protein reagents provides exciting
prospects for future biomedical application. In either case, the manipulation of
T3SS for human benefit will require highly refined mechanistic models of T3SS
function. Drawing on research from multiple disciplines and employing
complementary techniques, such models are beginning to emerge. In particular,
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the application of structural biochemical approaches to the T3SS has provided
numerous insights into the assembly and function of this system.
The focus of this chapter will be on T3SS function at the structural level; I
will summarize the core findings that have shaped our understanding of the
structure and function of these systems and highlight recent developments in the
field. In turn, I will describe the T3SS secretory apparatus, consider its
engagement with secretion substrates, and discuss the post-translational
regulation of secretory function. Lastly, I will close with a discussion of the future
prospects for the interrogation of structure-function relationships in the T3SS,
and highlight those that will be the focus of the remaining chapters of this thesis.

1.2 Architecture of a nanosyringe
The genomic islands and virulence plasmids that support T3SS encode proteins
of four broad classes: the components of the secretory system itself, the effector
substrates, their chaperones, and transcriptional regulators. Working in concert,
these components form a complete secretory system that de-chaperones and
secretes substrates in a defined hierarchy and delivers them to the host
cytoplasm. The repertoire of effector proteins secreted by a given T3SS is
species-specific, as is the transcriptional network regulating T3SS expression
(10). A discussion of these elements is beyond the scope of this document and
has been expertly reviewed elsewhere (11-20). In contrast to the diverse,
species-specific catalog of effector proteins and transcriptional regulators, the
nanosyringe-like secretory machinery is well-conserved across species, and
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advances in our mechanistic understanding of one species’ injectisome are often
applicable to others.
The core secretion machinery of the T3SS comprises a homologous set of
approximately two-dozen gene products. Because of the high degree of
homology of some components of the system, a universal nomenclature was
previously suggested to facilitate cross-species comparisons (21), and recently
others in the field have endorsed this naming system (22, 23). Similarly, I will
employ this nomenclature (Table 1.1) wherever possible in this chapter.
A subset of these proteins have conserved homologues in the flagellar
apparatus (Table 1.1), which uses its own T3SS machine to assemble the
flagellar filament (24). The flagellar apparatus employs a number of proteins for
the flagellar-specific function of torque generation, and not surprisingly these
components lack homologues in the injectisome. However, a set of inner
membrane and cytoplasmic proteins thought to be involved in the targeting and
secretion of substrates is conserved between the two systems. Given that these
T3SS subtypes appear to have diverged from a common ancestor some
hundreds of millions of years ago (25), their conservation is noteworthy. While the
focus of this chapter and the majority of this thesis is the injectisome T3SS
subtype, I will draw on the flagellar literature where it offers insights into
injectisome function, and a subset of these flagellar homologues will be revisited
in depth in Chapter 4.
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Table 1.1: A unified nomenclature for the homologous core components of
the T3SS. Based on the nomenclature proposed by Hueck (21), with
modifications and additions from (20, 22, 23, 26).

Notes

Basal Body

Universal
nomenclature

Salmonella
SPI-1

Shigella

EPEC

Yersinia
spp.

Pseudomonas
aeruginosa

SctC

InvG

MxiD

EscC

YscC

PscC

SctD

PrgH

MxiG

EscD

YscD

PscD

SctJ

PrgK

MxiJ

EscJ

YscJ

PscJ

InvH

MxiM

YscW

ExsB

Pilotin

Flagellar
Appparatus

Inner Rod

SctI

PrgJ

MxiI

EscI

YscI

PscI

Needle
Fliament

SctF

PrgI

MxiH

EscF

YscF

PscF

Needle
Length
Regulator

SctP

InvJ

Spa32

EscP
(Orf16)

YscP

PscP

FliK

SctV

InvA

MxiA

EscV

YscV
(LcrD)

PcrD

FlhA

SctR

SpaP

Spa24

EscR

YscR

PscR

FliP

SctS

SpaQ

Spa9

EscS

YscS

PscS

FliQ

SctT

SpaR

Spa29

EscT

YscT

PscT

FliR

SctU

SpaS

Spa40

EscU

YscU

PscU

FlhB

SipB

IpaB

EspD

YopB

PopB

SipC

IpaC

EspB

YopD

PopD

SipD

IpaD

EspA

LcrV

PcrV

SctN

InvC

Spa47

EscN

YscN

PscN

FliI

SctO

InvI

Spa13

EscO
(Orf15,
EscA)

YscO

PscO

FliJ

SctQ

SpaO

Spa33

SepQ

YscQ

PscQ

FliM/FliN

SctK

OrgA

MxiK

SctL

OrgB

MxiN

EscL

YscL

PscL

FliH

SctW

InvE

MxiC

SepL/
SepD

YopN/
TyeA

PopN

Inner
Membrane
Integral
Components

Needle Tip
and
Translocon

ATPase
Coiled Coil
Linker

Sorting
Platform

Export
Regulator

YscK
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The core conserved proteins of the T3SS form a double-membrane-spanning
syringe-like structure (27, 28), including its extracellular needle-like appendage,
and the associated cytoplasmic and membrane-integral secretion machinery
(Figure 1.1). These components are collectively responsible for the delivery of
effector proteins into the cytosol of the eukaryotic host cell (29, 30), and their
structural and biochemical characterization has yielded significant insights into
the processes of machine assembly and substrate secretion.

The basal body. The bacterial double membrane and peptidoglycan layer are
spanned by a stack of protein annuli known as the basal body (Figure 1.1). It
comprises an outer membrane-anchored layer (SctC) and an inner membraneanchored layer (SctD and SctJ) that interface at a “neck” (31, 32). In electron
microscopic (EM) reconstructions of the injectisome, SctC forms two distinct
outer rings (OR1 and OR2), SctD and SctJ together form the distal inner ring
(IR1), and the cytoplasmic amino terminus of SctD forms the innermost ring (IR2)
(31). The highest resolution cryo-EM models of the Salmonella basal body reveal
an overall three-fold rotational symmetry, with a resultant symmetry mismatch
between the inner and outer layers: each basal body contains 24 SctD
molecules, 24 SctJ molecules, and 15 SctC molecules (32). While the 24-fold
symmetry of the inner membrane rings appears conserved across T3SS (33, 34),
the stoichiometry of the the SctC outer membrane ring may vary between
species (12-15 molecules per basal body), such that some systems have an
overall 12-fold rotational symmetry (34, 35).

6

Figure 1.1: Gross architecture of the T3SS. Cryo-EM reconstruction of the
Salmonella typhimurium injectisome basal body at subnanometer resolution
reveals its overall architecture. (A) Surface representation of

the highest

resolution cryo-EM map (EMD 1875, contour level 0.0233) published by Marlovits
and colleagues (32). Dashed lines indicate the positions of bacterial membranes
in vivo. Abbreviations used: OR, outer ring; IR, inner ring; OM, outer membrane;
IM, inner membrane. (B) An axial section through the map in (A). (C) Transverse
sections through the map in (A) at the level of the neck (left) and IR1 (right).
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SctC is homologous to the Type II secretion system secretins (9, 36), and like
other secretin family members requires a pilotin lipoprotein for its optimal
localization and assembly (37-39). The membrane-embedded, β-rich region at
the SctC carboxy terminus can be isolated and has been visualized by EM (35),
but it has yet to be characterized at moderate or high-resolution. The periplasmic
amino terminus of SctC contains a modular domain architecture (40) that
interacts with the inner membrane ring (41, 42).
SctD and SctJ form the inner membrane rings (31). Each is anchored to
the membrane by a single transmembrane helix, and SctJ is additionally lipidated
near its amino terminus (43). Like the amino-terminal periplasmic region of SctC,
the periplasmic domains of SctD and SctJ comprise a modular multidomain
architecture (40). Despite differences in connectivity and little sequence
homology, the mixed α/β domains of SctC, SctD, and SctJ show a similar threedimensional structure: two α-helices pack against the same face of a three strand
β-sheet (40, 44). Superhelical crystal packing of the E. coil SctJ periplasmic
region provided initial insights into the mechanism of inner membrane ring
assembly (43), and the modular arrangement of these domains seems to
promote oligomerization (45); however, none of these domains have been shown
to clearly form annuli in solution, suggesting that additional constraints (e.g.
protein-protein interactions or lipid membrane planarity) are critical for ring
formation. Similarly, despite their 1:1 stoichiometry in the basal body, the
periplasmic domains of SctD and SctJ have not been crystalized in complex.
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Might there be a specific functional advantage for the modular domain
architecture common to the SctCDJ periplasmic regions? Recent in situ electron
tomography of the Yersinia and Shigella injectisomes shows that the basal body
has the ability to stretch in response to osmotic expansion of the periplasmic
space (34). This resilience could be of potential importance for the maintenance
of intact T3SS injectisomes under physiologic stresses and membrane
deformations (34). Molecular dynamic simulations suggest that relative motions
of the SctD periplasmic domains could account in part for this flexibility (34), but
this hypothesis requires empiric support.
The amino-terminal cytoplasmic domain of SctD forms the innermost ring
of the T3SS basal body. High-resolution structural analyses have determined this
domain to have a forkhead-associated fold that interacts with cytoplasmic
components of the T3SS (46-49). Forkhead-associated domains are βsandwiches that typically serve as phosphothreonine binding scaffolds,
suggesting a means of signal-dependent recruitment of the cytoplasmic secretory
apparatus to the basal body. However, the potential phosphopeptide binding
residues are not conserved among T3SS (48), and the precise nature of the
interactions between SctD and the cytoplasmic apparatus remains to be
determined.
Within the central lumen of the basal body annuli, SctI is believed to form
a cylindrical “inner rod” (31) structure that may support the extracellular needle
filament. Computational methods have suggested a predominantly α-helical
structure for SctI similar to that of the needle filament protomer (below); however,
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structural analyses of Salmonella and Shigella SctI in solution showed little
secondary or tertiary structure (50). It remains to be determined whether SctI can
adopt a stable fold within the confines of the basal body. The functional
significance of the inner rod in the regulation of needle length and secretion
substrate switching will be discussed below.
Direct structural characterization of the T3SS basal body epitomizes the
challenges associated with the interrogation of high-molecular weight
macromolecular machines: the assembly spans two membranes and a layer of
peptidoglycan, and in situ electron tomographic analyses suggest that the basal
body is capable of substantial conformational dynamism (34). As direct, highresolution structural characterization of the assembled T3SS basal body has not
yet been possible, a multidisciplinary approach integrating cryo-EM maps, X-ray
crystallographic domain structures, biochemical analyses and computer modeling
has yielded a high-probability static model for injectisome architecture (51)
(Figure 1.2). Such “hybrid” models will allow the testing of molecular-level
hypotheses about ring assembly until the structure of the T3SS basal body has
been determined at high-resolution in toto.
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Figure 1.2: Hybrid models of basal body structure. (A) Computational
modeling of the neck (SctC, PDB 3J1V), IR1 (SctD, PDB 3J1X), and IR2 (SctD,
PDB 3J1W) annuli of the Salmonella typhimurium basal body. No high resolution
structural information is available for the basal body above the neck. (B) In this
model, complementary electrostatic surfaces support ring building, as shown for
the SctD periplasmic domains.

Note the modular domain architecture

(enumerated 1, 2, 3) for SctDperiplasmic.
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The inner membrane machinery. Five highly conserved inner membrane proteins
(SctRSTUV) are necessary for the function of the pathogenic T3SS; however
their individual functions are unclear. It is worth noting these proteins show a high
degree of sequence homology to components of the evolutionarily related
flagellar T3SS (Table 1), and may represent a functional core, serving critical
chemical roles in initiating or powering protein secretion.
Among the SctRSTUV cohort, SctU and SctV possess cytoplasmic
domains in addition to their transmembrane helices, and these domains have
been best characterized to date. The cytoplasmic region of SctV contains a
modular array of small domains (52-54) and crystallographic data suggest SctV
may nonamerize (54). Intriguingly, such an oligomer is well suited to fit in a torus
of SctV-associated density observed 5-10 nm beneath the basal body in EM
reconstructions of the T3SS (34, 54). Lea and colleagues (54) have forwarded
the hypothesis that this SctV homo-oligomer may serve as a “cage” to facilitate
the complete unfolding of folded or partially unfolded secretion substrates, but
this possibility has not yet been experimentally validated. The cytoplasmic region
of SctU is considerably smaller than that of SctV and contains an autoprotease
(55); its potential role in the regulation of secretion will be discussed below.
SctRSTUV are important in the organized, stepwise assembly of the T3SS
basal body. Galán and colleagues (56) employed a combination of genetic and
structural approaches to show that SctRSTUV help to organize the SctDJ inner
membrane rings. Subsequently, the SctC ring and cytoplasmic machinery (below)
are recruited, and the inner rod and needle polymers assembled (23). While
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SctRSTUV are individually not strictly necessary for the formation of the SctCDJ
basal body, the efficiency of basal body assembly is significantly decreased in
their absence (56).

The needle filament. A needle-like filament tens of nanometers in length
protrudes from the extracellular face of the T3SS basal body (27, 57). The needle
is formed by a helical assembly of the protein SctF, with an outer diameter of 8
nm and an inner pore diameter of 2.5 nm (58). The apparent similarity of the
T3SS basal body and needle filament to a macroscopic syringe makes it
tempting to speculate that the T3SS directly injects its substrates into the host
cell cytoplasm, with the needle filament serving as a conduit for the passage of
partially unfolded effector proteins. Until recently, this hypothesis lacked direct
empirical support, and alternative “non-injectisome” models for T3SS effector
delivery had been proposed (59). Analyzing substrate-trapped injectisomes by
cryo-EM, Marlovits and colleagues (60) and Kolbe and colleagues (61)
demonstrated the presence of additional density in the lumen of the T3SS needle
filament, consistent with the passage of partially unfolded substrate molecules
through the needle.
High-resolution structures of monomeric SctF mutants (62) or chaperonebound SctF (63, 64), have allowed the characterization of the needle protomer
fold.

SctF is a hairpin of alpha helices with an intervening conserved PXXP

motif. The oligomeric nature of the needle filament had posed a practical barrier
to high-resolution structure determination for the intact assembly. Recent hybrid
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approaches combining cryo-EM with solid state nuclear magnetic resonance
spectroscopy (NMR) and computational modeling have since afforded such a
model for both the Salmonella (58) and Shigella (65) needle filaments. In these
models, the SctF amino terminus is oriented towards the convex needle exterior,
the carboxy terminus towards the lumen, and the apex loop connecting the two
alpha helices points away from the bacterium. It should be noted that this
arrangement is in contrast to prior lower resolution models (66), which oriented
the SctF amino terminus towards the needle lumen. This correction is significant:
the orientation of SctF protomers in the solid state NMR models is such that the
lumen walls are formed by highly conserved residues, consistent with the
passage of secretion substrates through the lumen (58, 65).
Assembly of needle filaments of a given length is necessary for the proper
infectivity of T3SS-bearing pathogens, possibly matching the dimensions of hostpathogen adhesion complexes (67). How, though, is the length of the needle
filament controlled? SctP regulates the length of the needle filament in several
species (68-70). In Yersinia spp., the number of residues in SctP correlates with
needle filament length, leading to the hypothesis that SctP functions as a
“molecular ruler” (70). That is, SctP might attach at one end to the basal body or
cytoplasmic apparatus and at the other end to the growing needle filament, and
once SctP was stretched beyond a given length, it would signal to the secretion
apparatus to change substrates.
In contrast to the molecular ruler model, work in Salmonella suggest that
SctP regulates needle length through control of inner rod assembly (57).
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Salmonella lacking SctP show decreased density in the inner rod-supporting
socket region, lack a polymerized inner rod, and generate long needles (57, 71).
Accordingly, Galán and colleagues hypothesized that completion of inner rod
assembly terminates needle growth in a SctP-dependent fashion. Consistent with
this “timer” model of length control (23), overexpression of SctF or SctI leads to
longer or shorter needles, respectively (57). Moreover, alanine-scanning
mutagenesis analyses of the inner rod protein SctI in Salmonella revealed
numerous point mutations that increased needle length without compromising
secretory function, perhaps by slowing the rate of inner rod polymerization (71).
Intriguingly, the elongated needles generated by most of these mutants remained
attached to the basal body (71), in contrast to those produced by sctP deletion
mutants, which are easily sheared off (57). This observation is consistent with the
hypothesis that the polymerized inner rod joins with the needle filament,
anchoring it to the basal body (71).

The needle tip and translocon pore. At the tip of the T3SS needle filament is a
pentameric cap formed by the hydrophilic translocator protein (72, 73). The
needle tip is believed to interact directly with the host cell surface to facilitate the
insertion of a multimeric pore (74, 75), thus completing the cytoplasm-tocytoplasm protein conduit. The structure and function of the needle tip is of
particular biomedical interest, as the hydrophilic translocator protein is a
protective antigen in anti-Yersinia vaccine formulations (76) and is a target of
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recently developed passive immunization strategies for the treatment of
Pseudomonas aeruginosa infections (77).
X-ray crystallographic analysis of the monomeric tip protein from several
species reveals some conserved architectural features (78, 79): the tips of all
species show an elongated coiled coil region and a central mixed α/β
subdomain. The overall structure of the tip protein shows some interspecies
variation though, with Salmonella/Shigella SipD/IpaD possessing an aminoterminal autochaperoning subdomain (79) lacked by the Yersinia/Pseudomonas
LcrV/PcrV tip proteins (23, 75). High-resolution models of the pentameric needle
tip are not available, but low resolution negative stain EM models have offered
some insight into the organization of the needle tip. While both appear
pentameric, the Shigella tip complex is narrow and elongated relative to that of
the Yersinia tip (72, 73), and fitting the Shigella IpaD monomeric crystal structure
into the EM map required a significant rearrangement of the mixed α/β domain
(73), suggesting substantial conformational changes upon incorporation into the
tip complex.
Attempts to model the tip protein-needle filament interaction at highresolution using NMR or X-ray crystallographic data have so far proven
challenging, with incompatibilities arising between the proposed models and
other data sets (80-82). The crystal structure of a Salmonella SctF-SipD fusion
protein identified a potential binding mode for the tip with the needle (80);
however, modeling the fusion structure onto the solid state NMR model of the
needle filament (58) resulted in steric clashes, suggesting that artifactual
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constraints imposed by the protein fusion strategy biased the architecture of the
complex (82). Regardless, a synthesis of the available data shows that the
needle filament interacts with the tip protein at least in part through its elongated
coiled coil, a motif observed in all T3SS tip proteins described to date.
EM and biochemical analyses have shown that the Shigella tip complex is
actually a heteropentamer containing four copies of the hydrophilic translocator
IpaD and one copy of the hydrophobic translocator IpaB (81). A refined tip model
incorporating this insight is similar to previous models, in that the amino and
carboxy termini of IpaD are oriented towards the needle filament, with portions of
the coiled coil region contacting the needle. However, the refined model presents
an IpaD orientation consistent with antibody binding data and the
heteropentameric architecture explains the transition from a helical needle
filament to a nearly flat-topped tip complex (81).
In contrast to the annular, pentameric tip complexes observed for other
T3SS, enteropathogenic E. coli possess a long filamentous needle accessory
comprised of EspA, the SipD/IpaD/LcrV/PcrV homologue (83). EspA forms a
helical filament similar to the SctF needle, with an internal diameter of
approximately 2.5 nm (84), suggesting that it functions to extend the T3SS
transport conduit. Filling a functional niche similar to needle filament length
control in other T3SS, E. coli EspA polymers may adapt the injectisome to reach
the target cell membrane beneath the intestinal glycocalyx (75).
The translocon permeating the host cell membrane is formed by the
hydrophobic translocators SipB/SipC in Salmonella and their homologues (Table
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1). Experiments in red blood cell membranes have shown that the needle tip is
crucial for the insertion of the hydrophobic translocators into the host membrane
and/or the organization of inserted translocators into functional pores (74, 85).
While numerous experimental approaches have been employed to characterize
the pore diameter and structure of the translocon (75), direct structural
interrogation of native translocons is lacking. Intriguingly, the amino-termini of
Salmonella SipB and Shigella IpaB contain extended coiled coils reminiscent of
the colicin family of bacteriocins (86), which are known to function in the delivery
of protein toxins across bacterial membranes. However, the precise mechanisms
of host cell recognition, membrane insertion, pore formation, and protein
translocation remain unclear for the T3SS translocon.

1.3 Substrate recruitment and secretion
T3SS secrete only a small fraction of the proteins present in the bacterial cytosol
(87), and do so in a defined hierarchy. How does the T3SS select its substrates,
how is their secretion hierarchy maintained, and what is the mechanism of
secretion? A combination of genetic, biochemical, and structural data provide
insight into the role of cytoplasmic injectisome-associated proteins in these
processes.

Secretion chaperones. The amino-terminal ~100 amino acids of T3SS substrates
possess two secretion signals: an unstructured extreme amino terminus followed
by a chaperone-binding region. While the extreme amino-termini of T3SS
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substrates are highly variable, computational approaches have identified
commonalities in the chemical composition of this secretion signal (88-90): the
first ~15 amino acids in an effector sequence are enriched in serine, threonine,
isoleucine, and proline. Indeed, an effector with a synthetic, amphipathic polyserine/isoleucine secretion signal was secreted by Yersinia even in the absence
of the second secretion signal (its secretion chaperone) (91). However, other
studies have shown that chaperone-substrate interactions are necessary for
targeting substrates specifically to the injectisome T3SS, as the extreme aminoterminal secretion signal sequence can facilitate injectisome substrate export
through the flagellar apparatus in the absence of a chaperone-binding domain
(92). This finding suggests that the extreme amino-terminal secretion signal is
evolutionarily “ancient” and shared by both types of T3SS (92).
Downstream of the amino-terminal secretion signal, each secretion
substrate is recognized by a specific chaperone protein that maintains the bound
region of the substrate in a partially unfolded state (93). It is hypothesized that
this nonglobular conformation primes the substrate for secretion through the
narrow aperture of the T3SS conduit (94). Chaperones can be classified by their
structure and substrate type (26), as follows: Class IA chaperones are mixed α/β
homodimers that bind to one effector; Class IB are structurally similar to IA but
bind multiple effectors; Class II are alpha helical tetratricopeptide repeat (TPR)
proteins that bind to translocon proteins; and Class III are heterodimeric TPR
proteins that bind SctF needle filament protomers. It should be noted that while
the premature polymerization of SipD/IpaD tip proteins is prevented by their
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autochaperoning domain (79), tip proteins in Yersinia and Pseudomonas utilize a
unique chaperone (LcrG/PcrG) to stabilize their tip protein monomers (95).
Like the extreme amino-terminal secretion signal, the chaperone-binding
sequences of secretion substrates are variable. However, Class I chaperone
recognition of a conserved β-strand(s) is a common feature of a diverse array of
T3SS effectors (96), and it is conserved from animal to plant pathogens (97)
(Figure 1.3). Indeed, the sparse sequence conservation associated with the “βmotif” (96) can be used to recognize previously unknown T3SS effector proteins
(98). In contrast, Class II and III TPR chaperones can recognize substrate
sequences in either extended unstructured or α-helical conformations; the
commonality here is that the TPR concavity is used to bind the substrate (26)
(Figure 1.3).
The aforementioned substrate secretion signals are not only necessary for
protein secretion through the T3SS, they are sufficient. Fusion of the secretion
signal and chaperone-binding domain from endogenous T3SS substrates to
heterologously expressed proteins results in their secretion through the T3SS
(99), provided they can be properly unfolded for transit through the needle (60,
61). While this observation is noteworthy for its mechanistic insight into the
targeting of virulence factors for secretion, it has allowed the benevolent reengineering of the system to deliver protective antigens in vaccine design (100)
and the large scale production of challenging protein reagents, like spider silk
(101).
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Figure 1.3: Chaperone-substrate interactions. Structural distinctions between
effector-chaperone and translocator-chaperone complexes. (A) The structure of
the Salmonella effector SipA chaperone-binding domain (CBD, red and yellow) in
complex with the Class IB chaperone InvB (2 protomers: dark gray and light
gray). PDB 2FM8 (52). The structurally conserved β-motif is highlighted in yellow.
(B) The SipA β-motif is bound by a hydrophobic (gray) patch on the InvB surface
(blue/gray). (C) Superposition of the CBDs from effectors from multiple species
shows a common binding mode marked by the structurally conserved β-motif.
The prototypical Class I chaperone SicP is shown in place of the various
chaperones. PDB codes: YopN, 1XKP (102); YopE, 1L2W (103); YscM2, 1TTW
(104); SptP-SicP, 1JYO (93); SipA, 2FM8 (52); HopA1, 4G6T (97). (D) The
Yersinia translocator YopD CBD (red) lacks secondary structure and is bound by
the concave cleft of the Class II chaperone SycD (gray). PDB 4AM9 (105).
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The ATPase. Both the injectisome and flagellar T3SS include an ATPase with
notable sequence homology to the β subunit of the F0F1 ATPase (106). For the
injectisome, this ATPase is SctN; for the flagellar apparatus, FliI (Table 1.1). Highresolution structural analysis of the E. coli SctN catalytic domain showed
similarities to V- and F-type ATPases and confirmed that SctN hexamerization
would be required for efficient ATP hydrolysis (107). Both FliI (108, 109) and SctN
(106, 110) form such oligomers, but neither has been characterized structurally
as a catalytically active hexamer.
Interaction of chaperone-substrate complexes with the T3SS ATPase SctN
causes the dechaperoning and unfolding of the substrate in an ATP hydrolysisdependent fashion (111). Given that disruption of tertiary structure is necessary to
fit protein substrates in the 2.5 nm conduit of the needle filament (60, 61), it is not
surprising that loss of function mutations in SctN cause the near complete
abrogation of T3SS function (106, 111). Similarly, genomic deletion of fliI severely
compromises flagellar filament assembly (112-115). Consistent with the role of
SctN in preparing substrates for export, SctN/FliI-dependent density is observed
directly beneath the T3SS basal body by EM (116, 117). The partial structural
similarity of SctO/FliJ with the γ-subunit of F-type ATPases and the ability of FliJ
to stimulate FliI hexamerization (109) has led to the hypothesis that this coiled
coil containing protein (118) might connect oligomeric SctN to the SctV export
gate, thus linking the sub-basal body toruses of electron density (54). However,
the mere presence of a coiled coil is insufficient evidence to ascribe a γ-like
function to SctO (23), and its precise role remains to be determined.
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Given the ATPase activity of SctN/FliI, it is tempting to speculate that ATP
hydrolysis provides the free-energy for protein secretion; however, chemical and
genetic analyses show that SctN/FliI is not the sole energizer of the T3SS.
Experiments with the protonophore carbonyl cyanide m-chlorophenyl hydrazone
have shown that the inner membrane proton motive force is necessary for
secretion by both injectisome (119) and flagellar (112, 113) T3SS. Additionally,
the flagellar assembly defect of ATPase deletion mutants can be at least partially
corrected by mutations that alter the export apparatus, increase substrate levels,
or increase the magnitude of the proton motive force (112-114). A similar result
was recently reported for SPI-1 T3SS in Salmonella (114). These results suggest
that under sufficiently permissive conditions, the actual transit of substrates into
and/or through the conduit is powered by the proton motive force. However, one
must interpret these results with some caution, as ionophores can significantly
perturb cellular physiology (120) and SctN-independent injectisome secretion of
a substrate requiring dechaperoning has not yet been demonstrated (114). A
reasonable synthesis of the available data might surmise that both ATP
hydrolysis and the proton motive force are important for energizing T3SS: the
SctN/FliI ATPase functions to dechaperone and begin unfolding the secretion
substrates with optimal efficiency under (non-ideal) physiologic conditions, while
the proton motive force is responsible for the apical transit of the nonglobular
substrate (114).
Regardless of the quantitative contributions of either energy source, the
mechanics of secretion remain poorly understood. There are no available high-
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resolution structural models of the interaction between chaperone-substrate
complexes and the SctN ATPase. One computational model suggests a mode of
ATPase-chaperone interaction based on structural similarities between Class I
chaperones and the F-type ATPase γ-subunit (121). While this model and the
accompanying biochemical data are consistent with the observation that
relatively carboxy-terminal residues of SctN interact with chaperones (121), its
structural accuracy lacks empiric support. Recent small angle X-ray scattering
(SAXS) data suggest an alternative model for the interaction of substrates,
chaperones, and the ATPase. Complexes of the Salmonella effector-chaperone
pair SopB-SigE are able to hexamerize in a concentration dependent manner
with dimensions comparable to the hexameric models of the ATPase (122). While
it is too early to say whether other chaperone-effector complexes can oligomerize
(123), whether these oligomers can interact with SctN, or whether such
interactions — even if physically possible — are physiologically relevant, these
results raise the possibility of alternate ATPase-cargo stoichiometries.
Recent solution NMR analyses suggest an interesting role for chaperone
structure in the targeting of substrates to the T3SS. In solution, the E. coli
chaperone CesAB is a partially folded molten globule (124) that does not interact
with the hexameric SctN (125). However, upon binding to its substrate — the
EspA tip filament protein — CesAB becomes fully structured and is able to bind
SctN (125). The binding site for SctN was mapped onto the CesAB-EspA
heterodimer, where it covered regions of CesAB unstructured in the absence of
substrate (125). Consistent with the hypothesis that substrate-induced folding of
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the chaperone allows for targeting to the ATPase, a mutation-stabilized,
structured CesAB homodimer was able to bind SctN in the absence of substrate
(125). While it remains to be determined whether similar disorder-to-order
transitions effect SctN binding for other chaperone classes, these results are
consistent with the role of chaperone-substrate interactions in targeting
substrates for secretion. Additionally, the observation that substrate-chaperone
complexes are recognized by hexameric SctN, but not its amino-terminally
truncated monomeric form, suggests that ATPase hexamerization is critical for
both hydrolytic catalysis and substrate recognition (125).

The sorting platform. Located at the peripheral cytoplasmic face of the flagellar
basal body is a ring of robust density in EM reconstructions (117). Known as the
“C-ring,” this annulus is composed of the flagellar proteins FliM, FliN, and FliG,
and it plays a role in flagellar motor function (torque generation) and rotational
switching (24). FliM and FliN have an injectisome homologue with some
conserved domains (SctQ), but torque generation by the injectisome is
controversial (126) and a robust C-ring is absent in tomographic reconstructions
of the injectisome basal body (34, 117). However, immuno-EM analysis of
purified Shigella injectisomes shows localization of SctQ to the cytoplasmic face
(127), suggesting that it plays some role in protein secretion or the regulation of
the secretory process. Indeed, recent cryo-electron tomographic analyses of the
Shigella injectisome have identified six SctQ-dependent “pods” of density
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proximal to the cytoplasmic face of the basal body, forming a structure distinct
from that of the flagellar C-ring (128).
Seminal biochemical and genetics work by Galán and colleagues revealed
that SctQ forms a critical “sorting platform” for the T3SS (129). Affinity purification
of SctQ from secretion-competent Salmonella produces high molecular weight
complexes containing the SctN ATPase, regulatory proteins, chaperones and
secretion substrates (129). Most notably, the sorting platform plays a role in the
hierarchical secretion of substrates, queuing substrates in their appropriate order.
For example, in Salmonella with assembled injectisomes, the sorting platform
was predominantly occupied by translocon proteins, but genomic deletion of the
translocators allowed the next tier of substrates (effector proteins) to access the
sorting platform (129).
In addition to SctQ, formation of the sorting platform required the proteins
SctK and SctL (129). While the role of SctK is at present unclear, biochemical
analyses of the flagellar apparatus shed light on the potential function of SctL.
SctL is a homologue of the flagellar protein FliH (Table 1.1). The SctL/FliH family
is predicted to have a conserved domain architecture: an amino-terminal
disordered region is followed by a coiled coil and then a mixed α/β domain (130).
The carboxy terminus of FliH interacts with the amino-terminal oligomerization
domain of FliI (130), inhibiting its ATPase activity (131). While sequence
similarities between the FliH carboxy-terminal domain and the F-type ATPase δsubunit suggest a role for FliH as a “stator” (132), it is not obvious that FliH
interacts with oligomeric FliI, and the structural details of this interaction are not
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yet known. The amino terminus of FliH interacts with FliN (133), and this FliHFliN interaction is important (134) — if not absolutely necessary (135) — for the
recruitment of FliI to the export apparatus. Given that the homologous
injectisome complex (SctQ-SctL-SctN) forms a portion of the sorting platform and
that chaperone-substrate complexes interact with the ATPase, these data
suggest that one function of the SctQ sorting platform could be to localize
chaperone-effector-ATPase complexes to the injectisome export apparatus.
Indeed, Minamino, Namba and colleagues have hypothesized that the ATPase
exists in two forms: an ATP-hydrolyzing hexamer and a dynamic substratecarrying monomer bound to FliH and the C-ring (136). Similarly, SctQ-injectisome
interactions are dynamic in Yersinia, as injectisome-associated SctQ exchanges
with a cytoplasmic pool with a half-time of approximately one minute (137).
Structural models of SctQ are a work in progress, and have focused to
date on the carboxy-terminal third of the molecule. In Pseudomonas syringae,
SctQ is spread over two open reading frames (hrcQA and hrcQB), much like FliM
and FliN in the flagellar system. The structure of the carboxy-terminal domain of
HrcQB is quite similar to that of the carboxy-terminal domain of FliN (138, 139);
both domains are homodimers of the “Surface Presentation Of Antigens” (SPOA)
fold, which appears to be unique to T3SS (Figure 1.4). The folded core of each
protomer is an antiparallel β-sheet, and a loop from each protomer containing a
β-strand and α-helix wraps around the β-sheet core of the other protomer. Like
two left hands grasping one another, an antiparallel beta-sheet “palm” of each
protomer is grasped by the “fingers” of the other, with a “thumb” protruding from
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the top of the palm and strands from each protomer forming an anti-parallel beta
sheet on the “floor” of the assembly.

Figure 1.4: The SPOA fold. (A) Ribbon model of the SPOA homodimer from
Pseudomonas syringae HrcQB (PDB 1O9Y) (138). One protomer is colored as a
rainbow from amino- (blue) to carboxy- (red) termini. Asterisk indicates the
location of the β-sheet floor. In keeping with the “two left hands” architectural
analogy, the “fingers,” “thumb,” and “palm” of one protomer are labeled. (B)
Topology diagram of the HrcQB SPOA homodimer; generated using Pro-Origami
(140). The rainbow pattern is not aligned between (A) and (B).
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In Yersinia, SctQ is the product of a single open reading frame (as in most
injectisomes), but the carboxy-terminal SPOA domain is duplicitously translated
from an internal translation start site (141). Structurally, this homodimer is
architecturally similar to its Pseudomonas and flagellar homologues. The
homodimer produced by this translation product is able to interact with full-length
SctQ and, at least in the Yersinia system, is necessary for secretion in vivo. In
both the flagellar (142, 143) and injectisome (144) systems, this SPOA domain
tetramerizes as a dimer of dimers, but appears to do so in different orientations in
each system. Cross-linking analyses suggest that the FliN SPOA tetramers form
a “doughnut” at the base of the C-ring (142), but high-resolution support for this
arrangement is lacking.
Despite the progress that has been made, numerous structural questions
remain unanswered for the SctQ sorting platform. The function of the SPOA
domain is unclear, SctQ-SctQ(SPOA) interactions have yet to be structurally
characterized, and the structural basis for the interaction of SctL with SctQ has
not yet been determined. Moreover, while the amino-terminal domains of FliM
have well characterized functions in the regulation of flagellar rotation switching
(145, 146), these motor functions are likely flagella-specific and involve
interactions with partners not conserved from the flagellar apparatus to the
injectisome (e.g. FliG and CheY). Thus, the function of the SctQ amino terminus
is also unclear. Lastly, how and when SctQ or its soluble interaction partners
interface with the basal body or export apparatus remains to be determined.
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Substrate switching. T3SS substrates are secreted in a defined order that is
necessary for the proper assembly and function of the system (147, 148):
secretion of the needle filament (SctF) and inner rod (SctI) is followed by
secretion of the needle tip protein and translocon pore proteins, which is followed
by the secretion of effector proteins. Thus, it seems that there are several
sequential substrate “switching” events that must occur for the hierarchical
secretion of substrates to be maintained (148).
The first such switching event halts the extension of the growing needle
filament and allows for secretion of the needle tip protein. As discussed above,
the length of the needle filament is controlled by the assembly of the inner rod in
a SctP-dependent fashion (57, 71). Full deletion of sctP locks the T3SS into a
mode of exclusive SctF filament secretion; that is, deletion of sctP results in not
only elongated needles, but a lack of translocon and effector secretion (68, 70,
149, 150). Indeed, deletion of sctP results in the absence of translocon
components from the SctQ sorting platform (129). However, small deletions in
the amino-terminal regions of SctP alter needle length without compromising
translocon secretion, suggesting that some portion of SctP performs a crucial
switching function (150). Deletions within the conserved mixed α/β region at the
carboxy terminus of the protein compromise translocon secretion (in addition to
disrupting needle length regulation), and this presumptive domain has been
termed the “type III secretion substrate specificity switch” (T3S4) domain (150).
The three-dimensional structure of an injectisome T3S4 domain has not
yet been determined, but the flagellar FliK T3S4 domain has been solved by
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NMR (151). The carboxy-terminal domain of FliK possesses two α-helices folded
against a four-strand β-sheet (151), and the predicted structural conservation of
these secondary structural elements in SctP suggests that this model may be
generalizable to the injectisome. While it is still unclear at the molecular level how
SctP functions to promote specificity switching, its interaction partners suggest
some viable hypotheses. For example, the SctP T3S4 domain interacts with the
SctO protein (152), suggesting that it may be able to transmit regulatory
information to the SctN ATPase or the SctV export gate. Moreover, the T3S4
domain interacts with the cytoplasmic autoprotease domain of SctU (153). Like
SctP, SctU regulates the secretion of the the inner rod protein (154). The
interaction between these two proteins is intriguing given that SctU interacts with
components of the SctQ sorting platform and the SctV export apparatus (155),
again suggesting mechanisms for the relay of switching information throughout
the secretory apparatus.
The second major switching event distinguishes between translocon
components and effector proteins (129). Deletion of translocon components
allows for the localization of effector proteins to the sorting platform, consistent
with a model where a gradient of substrate and/or chaperone affinities for the
sorting platform controls the hierarchy of secretion (129). The identification of
several classes of secretion apparatus mutants that can secrete effectors but not
translocon proteins offers some insights into the establishment of secretion
hierarchy. Deletion of sctW in Salmonella results in the specific loss of translocon
component secretion (147). SctW binds the translocon proteins and their
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chaperone in Salmonella (SicA) (147), and it is necessary for translocator binding
to the SctQ sorting platform (129). These observations are consistent with SctW
enhancing the affinity of translocon-containing complexes for the sorting platform.
However, recent genetics data suggest the mechanism of hierarchy control for
SctW may be more complex. A subset of the SctI alanine mutants identified by
Lefebre and Galán (71) have normal needle lengths but phenocopy sctW
deletion, and an interaction between SctW and SctI was recently reported in
Shigella (156). Together, these data raise the possibility of SctW binding not only
the sorting platform but also portions of the basal body.
Further clouding the role of SctW in T3SS is the observation of speciesspecific effects of sctW mutation. In Yersinia and Shigella, SctW is secreted and
sctW deletion does not specifically impair translocon protein secretion (157, 158).
Moreover, the Yersinia SctW protein pair YopN/TyeA is part of a complex calcium
response apparatus in the bacterial cytosol (159) that involves several Yersiniaspecific proteins (160, 161). While the structures of the Shigella and Yersinia
SctW homologues have been determined (102, 162), a fuller understanding of
SctW function (and its species-specific nuances) will require structural
characterization in complex with other injectisome components.
In addition to its role in the first switching event, SctU is also involved in
the second switch. The cytoplasmic domain of the SctU family autocatalyzes
cleavage between the asparagine and proline residues of its conserved NPTH
cleavage site (148). Alanine mutations on either side of the cleavage site cause
aberrant specificity switching: translocon proteins are no longer secreted but
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effector secretion remains intact (55, 157). An amphipathic linker connects the
SctU transmembrane region to the cytoplasmic autoprotease, and this linker
undergoes a disorder-to-order transition in the presence of anionic lipids (163).
Introducing charge-altering mutations in the linker impaired T3SS function,
suggesting that the ordering of the SctU linker against the bacterial inner
membrane is crucial, perhaps favorably orienting the autoprotease domain for
interactions with other members of the export apparatus (163). As mentioned
above, SctU interacts with multiple members of the sorting platform, but the
bases for these interactions — and the mechanisms by which they would effect
specificity switching — are unclear.

Control of secretion. The T3SS can assemble a basal body, needle and tip, then
pause in a “primed” state until the relevant stimulus arrives and secretion
resumes. This strategy prevents the wanton waste of translocon and effector
proteins. Interrogating this additional level of complexity is important to our full
understanding of the pathobiology of T3SS, and may suggest routes to antivirulence compounds that prevent the activation of otherwise structurally
competent injectisomes.
Bile salts play a regulatory role in the T3SS used by several enteric
pathogens. The interaction of bile salts with the Shigella tip complex promotes
IpaB recruitment to the tip, forming the heteropentameric tip complex described
above (81, 164). In contrast, bile salts suppress Salmonella SPI-1 T3SS function
(165). These observations provide an intriguing correlation between host
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gastrointestinal physiology and pathogen virulence that ties environmental
factors to the species-specific adaptation of the T3SS. Despite reports describing
the interaction of bile salts with monomeric Shigella IpaD (166) and Salmonella
SipD (80, 167), the structural basis for bile salt interaction with the intact tip
complex has yet to be determined in either species, and so the mechanism of its
regulatory activity remains unclear.
Contact with host cells stimulates the activation of T3SS in several species
(168-170). In Salmonella, contact with target cells stimulates the secretion of the
translocon proteins SipB and SipC (171), and in Shigella, interaction of the IpaDIpaB tip with liposomes resembling host cell membranes induces IpaC secretion
(172). It is tempting to speculate that contact of the needle tip with the host cell
sends a mechanical signal to the basal body and/or export apparatus that
reinitiates secretion (10, 23, 173). As the connecting factor between the host cell
surface and the basal body, the needle filament itself is a promising candidate for
force transduction. Specific needle filament protein mutations can trap the
Shigella T3SS in a constitutively active secretion mode, and one might
hypothesize that these mutations stabilize needle filaments in a post-contact
activated conformation (174). However, the filaments formed by these mutants
do not exhibit the gross conformational changes one might expect if the needle
filament architecture were transducing this signal (174). Alternatively, local
changes in the tip environment may permit the secretion of substrates trapped
within the needle by a closed tip, restarting secretion without requiring signal
transduction to the bacterial cytoplasm or basal body (173).
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Work from the Salmonella SPI-2 T3SS suggests a tantalizing third (and
non-mutually exclusive) possibility, that the needle is not only a conduit for
protein secretion, but a passageway for the diffusion of chemical signals (175).
Salmonella makes use of two T3SS: broadly, the SPI-1 T3SS promotes cell
invasion and subsequently the SPI-2 T3SS facilitates the formation of the
Salmonella Containing Vacuole (SCV), an intracellular environment for
Salmonella survival and replication (176). Holden and colleagues noted that
priming of the SPI-2 T3SS requires exposure of the bacteria to low pH (as would
be experienced in the endosomal compartment), but that triggering of effector
secretion required a return to neutral pH (175). It is noteworthy that the SPI-2
SctW protein was required for this transition (175), consistent with the apparent
role of SctW in translocon-to-effector specificity switching in other systems
(above). However, it is most intriguing that this switch required intact translocon
components, suggesting that the neutral pH signal may be transduced from the
host cell cytosol, through the translocon and needle, to the basal body and/or
export apparatus (175).

1.4 Summary
In the past 20 years, our models of T3SS structure and function have evolved
substantially, from the first visualization of the injectisome architecture, to the
high-resolution structural interrogation of many of its individual components.
Combining these insights with a plethora of genetic and biochemical data, the
molecular mechanics of this astounding secretory nanomachine are coming into
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focus. However, numerous questions remain — the answers to which are critical
to our understanding of bacterial virulence, the design of new therapeutics, and
the imaginative re-engineering of the system.
Despite the improvements in cryo-EM models of the injectisome, the
precise architecture of the membrane embedded components of the T3SS is still
unclear, as is the structural basis for their interactions with the soluble
components of the system. The native structures of the filament-bound needle tip
and the translocon in the host membrane must be determined to understand how
the extracellular environment regulates secretion, how proteins penetrate to the
host cytosol, and how to rationally design secretion-blocking vaccines. Although
the constituents of the cytoplasmic sorting platform have been identified, the
structural bases for their interactions are unknown: how the sorting platform
assembles, how substrate-chaperone complexes engage the system, and how
the numerous regulatory elements interact to govern a secretory hierarchy all
remain to be determined.
Answering these questions is likely to require a hybrid approach,
characterizing local interactions and large assemblies alike, and employing a
range of structural and molecular techniques. However, it is clear that highresolution models of intact macromolecular assemblies (e.g. basal body, needle
tip, translocon pore) would greatly advance the field. Much like the role that
atomic models of the ribosome have played in the interrogation of its multiple
functional states, one can imagine the watershed of insight that would come from
successful visualization of the injectisome or sorting platform in each of their
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several forms: needle-assembling, translocator-secreting, and effector-secreting.
Ideally, these mechanistic insights will allow the uncoupling of some pathogenic
gram-negative bacteria from virulence and/or the re-engineering of the
nanosyringe for the benefit of biotechnology.
The work described in this thesis makes strides towards the mechanistic
understanding of T3SS sorting platform assembly by applying structural,
biochemical, and genetic techniques to the characterization of SctQ/FliM/FliN
and their interactions with other sorting platform components. I will present the
molecular structures of distinct homotypic and heterotypic SPOA-SPOA
interactions in the Salmonella typhimurium SPI-1 sorting platform protein SpaO
(Chapter 2). In Chapter 3, I structurally characterize the interaction of the
heterotypic SPOA complex with a regulator of the SPI-1 ATPase and
demonstrate the necessity of the interaction for T3SS secretory function. Then, I
will present the homologous structures from the S. typhimurium flagellar
apparatus and compare and contrast them with their SPI-1 homologues,
providing an explanation for the observed subtype specificity in sorting platform
assembly (Chapter 4). In Chapter 5, biochemical evidence for an interaction of
the SpaO amino-terminal domain(s) with the homotypic SPOA complex is
presented. The implications of this work and potential future directions are
discussed in Chapter 6. Lastly, the materials and methods used in this study are
described (Chapter 7).
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CHAPTER 2:
SPOA-SPOA INTERACTIONS IN SpaO

Portions of Chapters 2-7 have been published previously (177):
Notti et al. (2015). A common assembly module in injectisome and flagellar
type III secretion sorting platforms. Nature Communications 6, 7125.

To date, the T3SS sorting platform has been most thoroughly characterized in S.
typhimurium (129). This species contains three T3SS: two injectisomes (SPI-1
and SPI-2, as discussed in Chapter 1) and a flagellar apparatus. As the genetic
and biochemical characterization of the sorting platform explored the SPI-1
constituents, I chose to begin my efforts there. For clarity and consistency with
the primary literature, I will now refer to the relevant SPI-1 gene products by their
Salmonella-specific names.

2.1 Expression and purification of SpaO
The major constituent of the SPI-1 sorting platform is a 303-residue protein SpaO
(SctQ) (129). SpaO was robustly heterologously expressed as a double
hexahistidine fusion in E. coli and yielded soluble material by nickel-affiinity
purification (Figure 2.1C). Like its Yersinia homologue, full length SpaO co-affinity
purified with a small fragment (~14 kDa). In Yersinia, the ~11 kDa YscQ fragment
is translated from an internal translation start site at M218 and is necessary for
T3SS function (141). While SpaO lacks a potential initiator methionine codon in
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this region of the gene, I hypothesized that a nearby valine GTG codon
(ValGTG203, arrow in Figure 2.1A) with a putative upstream ribosomal binding site
(Figure 2.1B) might be able to function as a cryptic translation start site. Indeed,
mutation of the Val203 codon from GTG to GTT resulted in the loss of fragment
expression and co-purification (Figure 2.1C). Intriguingly, in the absence of this
carboxy-terminal fragment, the soluble yield of full length SpaO protein was
greatly diminished, despite an identical amino acid sequence and overall similar
expression levels (Figure 2.1C).
The Yersinia YscQ carboxy-terminal fragment contains a SPOA domain as
previously seen in Pseudomonas HrcQB and the flagellar protein FliN.
Preliminary bioinformatic analyses — specifically, sequence homology and
secondary structure prediction — suggested the presence of two putative SPOA
domains in the carboxy-terminal half of SpaO, which we prospectively denote
SPOA1 and SPOA2 (Figure 2.1A). The presumptive SPOA domain located within
the cryptically translated carboxy-terminal fragment and at the carboxy terminus
of the full length SpaO protein was 34% and 24% identical to its Y.
pseudotuberculosis and P. syringae homologues, respectively, by Clustal Omega
alignment (178). (These two structurally characterized SPOA domains are 26%
identical to one another.) Putative SPOA1 showed lower sequence identity to the
structurally characterized SPOAs from Yersinia and Pseudomonas (18% and
19%, respectively), but showed 24% identity to S. typhimurium SPOA2 and
secondary structure prediction was consistent with a SPOA fold.
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Figure 2.1: Bioinformatic analysis and heterologous expression of SpaO.
(A) Secondary structure prediction and sequence homology suggest the
presence of two putative SPOA domains in SpaO. Approximate domain
boundaries are indicated beneath the block diagram. PSIPRED probability of
helical character is plotted in red, strand in blue, and disorder in yellow. The
arrow represents a predicted ValGTG203 internal translation start site. (B) SpaO
genomic sequence and amino acid translation in the vicinity of codon 203. Select
codon numbers appear at bottom. The putative cryptic translation initiation codon
is highlighted in red. A purine rich region 8bp upstream of ValGTG203 is denoted
as the hypothetical ribosomal binding site (RBS). (C) Heterologous expression of
SpaO in E. coli. Coomassie-stained sodium dodecyl sulfate (SDS)polyacrylamide gel electrophoresis (PAGE) gels showing the imidazole elution or
whole cell lysates for recombinant expression experiments. The genotype of
SpaO at codon 203 is shown over each lane and coexpression of the SPOA2
containing construct SpaO(222-303) is indicated with a “+”. Presumptive
chaperone contamination is indicated by a black asterisk. Red asterisks in the
whole cell lysate gel indicate the bands corresponding to SpaO(203-303) and
SpaO(222-303) (left and right, respectively).
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I hypothesized that the SPOA2 region of the cryptically expressed carboxyterminal SpaO fragment might mediate its interaction with the full length protein.
Indeed, coexpression of double hexahistidine tagged SpaO(1-303, ValGTT203)
with the SPOA2 construct SpaO(222-303) resulted in co-affinity purification of the
two polypeptides over NiNTA resin (Figure 2.1C). Furthermore, coexpression of
this SPOA2 containing fragment with the SpaO(1-303, ValGTT203) rescued the
protein’s solubility defect, restoring it to wild-type levels (Figure 2.1C) and
implicating the SPOA2 domain specifically in this phenotype.
Co-affinity purified complexes of full length SpaO with SPOA2-containing
constructs remained partially intact over anion-exchange chromatography, with a
fraction of SPOA2 separating from the full length protein (Figure 2.2A, compare i,
ii, and iii). However, intact complexes remained associated over size exclusion
chromatography (Figure 2.2B, see ii) and I endeavored to crystallize this complex
for structure determination by X-ray diffraction.
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Figure 2.2: Purification of the SpaO-SPOA2 complex. (A) Full length SpaO
and its co-purifying carboxy-terminal fragment were subjected to anion exchange
chromatography (left). The blue trace shows UV absorbance at 280 nm (A280)
and the brown trace shows conductance (G). At right, samples of the elution at
three points (i, ii, and iii) are shown on a coomassie-stained SDS-PAGE gel. (B)
Fractions of peaks “ii” and “iii” were further purified by size exclusion
chromatography (left), and samples of the elution are shown at right processed
and stained as in (A).
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2.2 Diffraction analysis of macromolecules: A brief overview
Before proceeding with further experimental description, it is prudent to briefly
discuss the methodology of X-ray crystallography, as it will be central to much of
the work presented here. (For a full resource, see Drenth and Mesters, ref. 180.)
Over the past century, X-ray crystallography has revolutionized our
understanding of small molecule and macromolecular structure by allowing the
determination of the positions of individual atoms within a macromolecule (179).
While it is now complemented by NMR spectroscopy and cryo-EM, X-ray
crystallography was the first technique to allow the visualization of
macromolecular structure at high (atomic or near-atomic) resolution.
In order to determine the structure of a protein or protein complex by X-ray
diffraction, the target must be packed into an ordered, three dimensional crystal
lattice by exposure to an empirically determined solution of precipitants, buffers,
salts, and additives. Exposure of the crystal to bright, collimated beams of X-ray
photons results in interactions of the protein’s electrons with the incoming
photons, changing their direction as they pass through the crystal. As a product
of the repeating nature of the crystal lattice, patterned constructive and
destructive interference of the scattered X-ray waves generates a stereotyped
three dimensional array of spots measurable by X-ray detection equipment (a
“diffraction pattern,” Figure 2.3). Individual spots are identified by integer indices
h, k, and l, and their intensities can be measured with high accuracy.
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Figure 2.3: X-ray diffraction analysis of macromolecules. Exposure of
crystalline macromolecules generates a diffraction pattern of “reflections.” The
intensity of these spots can be used to provide structural information about the
macromolecule crystallized.

From these intensities, one can calculate a map of the electron density within the
crystal lattice and build a molecular model of the crystallized protein’s structure
(180). The electron density (𝛒) at a given point (x,y,z) within the crystal’s
repeating unit cell is related to the diffraction pattern by Fourier transformation:

ρ (x, y, z) =

1
∑
V h

∑∑
k

F(h, k,l) e−2π i(hx+ky+lz)+iα (h,k,l )

l

where V is the volume of the crystalline unit cell, F(h,k,l) is derived from the
measured X-ray intensity at a given index (h,k,l), and α(h,k,l) is the phase angle
of the wave at that index. While the X-ray intensities can be measured directly,
the phase angles are not measured by the detector. This missing information
creates the “phase problem” of X-ray crystallography: without the phase data, the
electron density map cannot be determined from the X-ray diffraction pattern.
44

Phase information can be calculated by several methods, allowing for the
successful determination of molecular structure from diffracted X-ray intensities.
In this work, novel structures were solved by selenomethionine (SeMet) single
wavelength anomalous diffraction (SAD). Many proteins produced in E. coli are
compatible with the biosynthetic replacement of methionine sulfur atoms with
selenium. Protein crystals derived from this selenium-doped material generate Xray diffraction patterns with selenium position-dependent asymmetries
(“anomalous” diffraction). Whereas the intensities I(h,k,l) and I(-h,-k,-l) are
normally equivalent, this is no longer the case in the presence of a structured
anomalous scatterer, and these measurable intensity differences can be used to
determine Se positions and starting estimates of phase angles. For derivative
structures in this work, known partial structures were used to determine starting
phase estimates; this method is known as molecular replacement. In both cases,
an iterative approach is used refine the molecular model and inferred phase
angles against the empirical diffraction data until the fit between them has been
optimized.

2.3 Structure of the SpaO SPOA2 homodimer
Full length SpaO in complex with separately translated SPOA2 was subjected to
standard sparse matrix crystallization screening to generate crystals for
diffraction analysis. While several conditions grew tetragonal crystals, these
crystals were composed solely of the SPOA2 polypeptide and diffracted poorly.
No crystals containing the full length SpaO protein were identified.
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In order to facilitate structural characterization of SpaO, I attempted to
break SpaO into smaller domain constructs that might be more amenable to
crystallization. Ideally, structural characterization of small modules within the full
length protein might shed light on higher order structures or functions. Given the
inherent crystallizability of SPOA2, I decided to begin with this domain.
Using the aforementioned bioinformatic information and preliminary
diffraction data from SpaO(222-303), the SPOA2 containing construct was
truncated to SpaO(232-297). This construct was solubly expressed in E. coli, and
purified by Ni-affinity, anion exchange, and size exclusion chromatography
(Figure 2.4). Ghosh and colleagues previously used multiangle light scattering to
determine that the Y. pseudotuberculosis YscQ carboxy-terminal fragment exists
as a dimer in solution (141). Similarly, I subjected SpaO(232-297) to dynamic
light scattering (DLS) and found its hydrodynamic radius (20

Å ± 1

Å) and

resulting estimated mass (16 kDa ± 1 kDa) to be consistent with a dimer
(expected mass: 16 kDa) over a range of concentrations (Figure 2.4).
Crystals of SpaO(232-297) were obtained that routinely diffracted to high
resolution (all crystallization and cryoprotection conditions are available in
Chapter 7). SeMet incorporated SpaO(232-297) crystallized under the same
conditions as native material and diffraction data were collected to 1.35 Å
resolution (Figure 2.5 and Table 2.1). Given the high resolution data obtained
from SeMet crystals, the model was refined against the SeMet data set.
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Figure 2.4: Purification and solution behavior of SpaO(232-297). (A) Anion
exchange chromatographic purification of SpaO(232-297). The blue trace shows
UV absorbance at 280 nm and the brown trace shows conductance. Inset shows
coomassie-stained gel of the Ni-NTA resin imidazole elution (E) and the main
SourceQ elution peak (i). Note that the affinity tag was removed with human
rhinovirus 3C protease prior to anion exchange chromatography. (B) Size
exclusion chromatography purification of SpaO(232-297) subsequent to anion
exchange chromatography. Inset shows coomassie-stained gel of the main peak
(ii). (C) DLS data for SpaO(232-297). The data for 1mM protein is shown in the
autocorrelation and regularization graphs. In the autocorrelation graph, the raw
data is shown in blue and the regularization fit is shown in violet. Inset shows the
estimated particle mass over a range of concentrations.
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Figure 2.5: Diffraction analysis of SpaO(232-297). (A) Representative
diffraction image

for SpaO(232-297, SeMet). Image is truncated for fit. Edge

resolution is 1.25 Å. Inset shows an example of the crystal form. (B) Zoomed
view of the diffraction image in (A) highlighting high resolution spots. Resolution
values shown correspond to spots immediately to their left. (C) Stereoimage of a
selected region of the 2Fo-Fc electron density map for the 1.35 Å resolution
SpaO(232-297) structure. The map is contoured to 1σ.
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Table 2.1: Diffraction and refinement statistics for SpaO(232-297).
SeMet
PDB ID

4YX1

Space group

Data
Collection

P21

Cell: a, b, c (Å)

35, 41.27, 48

Cell: α, β, γ (°)

90, 103.92, 90

Resolution (Å)

31.26–1.35 (1.37–1.35)

Rmerge

0.146 (1.281)

I/σI

8.6 (2.1)

CC1/2

0.994 (0.750)

Completeness (%)

99.7 (100)

No. of reflections

29,246

Redundancy

7.0 (7.1)

Rwork/Rfree

0.1724/0.2053

No. of atoms

1,286
Protein

1,062

Ligand/ion

2

Water

Refinement

222

B factors: Protein

14.70

B factors: Ligand/ion

14.20

B factors: Water

32.10

Geometry (r.m.s.d.)
Bond lengths (Å)

0.007

Bond angles (°)

1.09

[Φ,Ψ] Favored (%)

98

[Φ,Ψ] Allowed (%)

100

[Φ,Ψ] Outliers (%)

0
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The structure of SpaO(232-297) confirms the fold of the presumptive SPOA2
domain as a bona fide SPOA fold (Figure 2.6). The construct forms a dimer in the
crystallographic asymmetric unit, in which each protomer interfaces with the
other in a “fingers-to-palm” arrangement, as described for the other structurally
characterized SPOA homodimers (Figure 1.4). The SPOA2-SPOA2 interface
buries 1898 Å2 from each protomer.
The conserved arrangement of β-strands is striking when comparing the
topology diagrams of SpaO SPOA2 (Figure 2.6) with its P. syringae homologue
(Figure 1.4). Indeed, the SpaO SPOA2 homodimer superposes on its Yersinia
and Pseudomonas homologues with 2.24 Å and 3.05 Å r.m.s.d., respectively. The
structural similarity is readily apparent, especially when viewing the structures
from the “top” (Figure 2.7A, right). Comparison of the SpaO SPOA2 sequence
with that of S. flexneri Spa33, Yersinia enterocolica YscQ, and P. aeruginosa
PscQ (Figure 2.7E) reveals that the greatest sequence homology maps to the
hydrophobic core and dimerization interface of the structure, as opposed to
solvent exposed surfaces (Figure 2.7B,C). Thus it seems that dimer formation is
likely to be a conserved structural feature of the SPOA2 domain, consistent with
all described crystal structures. The dimer architecture creates clefts on the “top”
and “bottom” of the assembly, and it is noteworthy that these crevices are
somewhat structurally conserved, displaying electronegative surfaces in S.
typhimurium and its homologues (Figure 2.7D, Y. pseudotuberculosis shown),
despite inconsistent sequence homology.
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Figure 2.6: Structure of the SpaO SPOA2 homodimer. (A) Ribbon diagram of
the SpaO(232-297) crystal structure. One protomer is shown in gray and the
other in green. The structure is annotated as SPOA diagrams previously shown;
asterisk indicates the β-sheet “floor.” (B) Topology diagram for the structure in (A)
generated using Pro-Origami.
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Figure 2.7: Comparison of SpaO SPOA2 with known homologues. (A) The
S. typhimurium, Y. pseudotuberculosis, and P. syringae SPOA2 homodimers are
shown as backbone worm diagrams, superposed, and colored as indicated. (B)
100% conserved (red) or highly conserved (orange) residues in the hydrophobic
core of the SPOA2 homodimer. A shell of highly conserved residues surrounds
F236. (C) Comparison of the degree of sequence conservation on the solvent
exposed (bottom) and dimerization interface (top) surfaces of a protomer in the
SPOA2 homodimer. Colored as in (B). (D) Electrostatic surface diagrams for the
S. typhimurium, and Y. pseudotuberculosis SPOA2 homodimers highlighting
structurally conserved electronegative clefts on the “top” and “bottom” of the
dimer (dashed circles). (E) Excerpt of the M-COFFEE alignment of SpaO, S.
flexneri Spa33, Y. enterocolica YscQ, and P. aeruginosa PscQ is shown
beginning with SpaO V232. Asterisk denotes identity; colon, high conservation;
period, low conservation.
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Figure 2.7: Comparison of SpaO SPOA2 with known homologues.
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2.4 Structural basis for SpaO SPOA1-SPOA2 interactions
Constructs containing only the presumptive SPOA1 domain were insoluble and
could not be refolded after affinity purification under denaturing conditions (Figure
2.8A,B). However, constructs containing both presumptive SPOA1 and SPOA2
(residues 140-297) were stable and soluble (Figure 2.8A). As this construct
contains the ValGTT203 mutation, no free SPOA2 is translated. Ni-affinity purified
SpaO(140-297) could be purified by subsequent anion exchange and size
exclusion chromatography (Figure 2.9); however, this construct did not yield
crystals when subjected to sparse matrix crystallization screening.

Figure 2.8: The putative SPOA1 of SpaO is stabilized by SPOA2. (A)
Heterologous expression of double hexahistidine-tagged SpaO SPOA1
(145-213) and SPOA1-SPOA2 (140-297) constructs in E. coli. A coomassiestained gel of the whole cell lysate (WCL) and soluble NiNTA imidazole elution
(E) are shown for each construct. Red asterisks denote expression of the
intended constructs as visualized in the WCL. (B) Attempted refolding of
SpaO(145-213). NiNTA elution under denaturing conditions (Urea E) and the
supernatant after refolding by dialysis and filtration of the insoluble material (RF
Super.).
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Figure 2.9: Expression and purification of SpaO(140-297). Anion exchange
(SourceQ, left) and size exclusion (Superdex75, right) chromatographic
purification of SpaO(140-297). The blue trace shows UV absorbance at 280 nm
and the brown trace shows conductance. Inset shows coomassie-stained gel of
the Ni-NTA resin imidazole elution (E) and the main anion exchange and size
exclusion chromatography elution peaks (i and ii, respectively). Note that the
affinity tag was removed with human rhinovirus 3C protease prior to anion
exchange chromatography (compare E and i).

To further characterize SpaO(140-297) in solution and refine expression
constructs for crystallography, I analyzed its backbone amide resonances by
solution NMR. Heteronuclear NMR experiments allow the identification of
resonances corresponding to individual backbone amide protons in a protein, all
of which can be simultaneously visualized in heteronuclear single quantum
coherence spectroscopy (HSQC) or transverse relaxation-optimized
spectroscopy (TROSY) spectra. As these resonances are very sensitive to the
immediate chemical environment of a given amide proton, a fully assigned HSQC
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or TROSY serves as the chemical “fingerprint” of a protein and offers insight into
local secondary structure and likelihood of disorder for a given residue (181).
SpaO(140-297) was analyzed by solution NMR and using a standard suite
of backbone assignment experiments, and 150 backbone amide proton
resonances were assigned out of a possible 155 (Figure 2.10). An example set of
linked, assigned amide resonances from one experiment in this suite (TROSYHNCA) is shown in Figure 2.10B. The overall impression from the 15N-TROSY is
one of a well dispersed pattern of amide resonances, consistent with a
structured, folded globular protein. A set of resonances with sharp peaks and
long relaxation times clustered around δ1H=8.25 is consistent with a region or
regions of disorder (e.g. flexible linker, extended surface loops, or disordered
termini). Chemical shift deviation analysis of backbone amide resonances
suggested a secondary structure pattern similar to that predicted by bioinformatic
analyses: two SPOA domains connected by a flexible linker (Figure 2.11).

Figure 2.10: NMR analysis of SpaO(140-297). (A)

15 N-TROSY

for

SpaO(140-297) annotated with backbone amide resonance assignments in red.
(B) Annotated strip-view of a portion of the TROSY-HNCA experiment used as
part of a suite of backbone assignment experiments. Linked resonances are
indicated with red asterisks connected with dotted lines.
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Figure 2.10: NMR analysis of SpaO(140-297)
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similar to bioinformatic predictions.

overall impression is one of two domains connected by a flexible linker. Secondary structure in each domain is grossly

chemical shifts. Predictions of residue order (top; green) and secondary structure (bottom; blue, strand; red, helix). The

Figure 2.11: Chemical shift deviation analysis of SpaO(140-297). TALOS+ analysis of SpaO(140-297) amide proton

The putative SPOA1 domain might be solubilized by the presence of SPOA2
(see Figure 2.8) in one of two ways: the two regions might interact directly,
burying otherwise aggregation prone surfaces, or the two regions might not
interact directly, and the presence of SPOA2 solubilizes SPOA1 simply by virtue
of its own high solubility. I hypothesized the former to be the case — that SPOA2
directly interacts with and solublizes SPOA1, perhaps in a manner structurally
analogous to SPOA2 homodimer formation. Consistent with this hypothesis, the
SPOA1-containing construct SpaO(145-213) could be co-refolded with SPOA2
(SpaO(232-297), Figure 2.12). Anion-exchange chromatography allowed the
separation of the SPOA1-SPOA2 complex (Figure 2.12, peak “i”) from excess
free dimeric SPOA2 (Figure 2.12, peak “ii”), and the complex remained stable
over size exclusion chromatography, despite lacking the polypeptide linker that
normally connects the two regions covalently.
One might hypothesize that the disordered region between the SPOA
domains (predicted by bioinformatics and supported by NMR chemical shift
analysis) might have previously been hindering crystallization, by virtue of its high
conformational entropy. Thus, I hypothesized that this linker-free SPOA1-SPOA2
complex might be more amenable to crystallization than SpaO(140-297). Indeed,
the SpaO(145-213) + SpaO(232-297) complex crystalized, and its structure was
determined to 2.9 Å resolution (Figure 2.13, Table 2.2). Compared to the SPOA2
homodimer crystals that diffracted to high resolution, the more weakly diffracting
SPOA1-SPOA2 crystals had a much higher solvent content (44% and 62%).
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Figure 2.12: Purification of SpaO(145-213) + SpaO(232-297). Anion exchange
(SourceQ, left) chromatographic purification of co-refolded SpaO(145-213) +
SpaO(232-297). The blue trace shows UV absorbance at 280 nm and the brown
trace shows conductance. Inset shows a coomassie-stained gel of the main
elution peaks (i, and ii). “1” indicates SpaO(145-213) and “2” indicates
SpaO(232-297). Peak “i” from the SourceQ elution was isolated from peak “ii”
and further purified by size exclusion chromatography (Superdex75, right). Inset
abbreviations are the same as those in the inset at left.
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Figure 2.13: Diffraction analysis of SpaO(145-213) + SpaO(232-297). (A)
Crystals of SpaO(145-213) + SpaO(232-297). (B) Representative diffraction
image of SpaO(145-213) + SpaO(232-297) crystals with the edge resolution
indicated. (C) Stereoimage of a selected region of the 2Fo-Fc electron density
map for the 2.9 Å SpaO(145-213) + SpaO(232-297) structure. The map is
contoured to 1σ and clipped to within 2 Å of the peptide for clarity.
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Table 2.2: Diffraction and refinement statistics for SpaO(145-213) +
SpaO(232-297).
SeMet
PDB ID

4YX5

Space group

Data
Collection

P41212

P41212

Cell: a, b, c (Å)

66.38, 66.38, 95.21

65.76, 65.76, 95.65

Cell: α, β, γ (°)

90, 90, 90

90, 90, 90

Resolution (Å)

46.94–3.00 (3.18–3.00)

38.68–2.9 (3.08–2.9)

0.221 (1.463)

0.166 (1.447)

11.8 (3.1)

14.4 (2.7)

0.989 (0.839)

0.996 (0.856)

Completeness (%)

100 (100)

99.3 (99.3)

No. of reflections

4,653

4,964

25.6 (27.2)

24.6 (26.2)

Rmerge
I/σI
CC1/2

Redundancy
Rwork/Rfree

0.2085/0.2795

No. of atoms

1,024
Protein

Refinement

Native

1,023

Ligand/ion

1

Water

0

B factors: Protein

74.20

B factors: Ligand/ion

105.00

B factors: Water
Geometry (r.m.s.d.)
Bond lengths (Å)

0.010

Bond angles (°)

1.33

[Φ,Ψ] Favored (%)

89

[Φ,Ψ] Allowed (%)

97

[Φ,Ψ] Outliers (%)

3
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Structure determination confirmed the presumptive SPOA1 region as having a
bond fide SPOA fold. SPOA1 and SPOA2 form a distinct, heterotypic SPOASPOA interaction with an overall topology similar to that observed in SPOA2
homodimers and a similar interfacial area (1799 Å2). The SPOA1 backbone
follows that of the prototypical SPOA fold, retaining the antiparallel beta-sheet
floor and fingers-to-palm architecture (Figure 2.14A,B).
SPOA1-SPOA2 and the SPOA2 homodimer superpose with 2.47 Å
r.m.s.d. (Figure 2.14C). The overall topology of SPOA2 in association with
SPOA1 is grossly similar to that seen in the homodimer (Figure 2.13D, r.m.s.d.
1.67 Å), but with some conformational alteration. In context, each thumb in the
SPOA1-SPOA2 complex is rotated clockwise towards its adjacent fingers relative
to the thumb positions in the SPOA2 homodimer (Figure 2.14E,F), creating a
shallower, less tall structure. To accommodate the SPOA1 thumb in this
orientation, the SPOA2 fingers are displaced relative to their position in the
homodimer. This displacement is the largest for the amide nitrogen of L256 (5.7
Å, Figure 2.14F).
To confirm that SPOA1 and SPOA2 interact outside of the solid-phase
crystalline environment, I re-evaluated previously acquired NMR data in the
context of the crystal structure. A post hoc analysis of the

15N-NOESY-HSQC

spectrum for SpaO(140-297) revealed long-range amide proton correlations
between SPOA1 and SPOA2 (Figure 2.15), consistent with association of the two
SPOAs in solution.
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Figure 2.14: Structure of the SpaO SPOA1-SPOA2 interaction. (A) Ribbon
diagram of the SpaO(145-213) + SpaO(232-297) crystal structure.
SpaO(145-213) is shown in cyan and SpaO(232-297) is shown in green. The
structure is annotated as SPOA diagrams previously shown; asterisk indicates
the β-sheet “floor.” (B) Topology diagram for the structure in (A) generated using
Pro-Origami. (C) SpaO(145-213, cyan) + SpaO(232-297, green) superposed on
the SpaO(232-297, gray) homodimer. (D) SpaO SPOA2 from the SPOA1-SPOA2
model (green) superposed in isolation on one protomer of the SPOA2
homodimer model (gray). (E,F) Worm diagrams derived from the alignment in (C)
highlighting the displacement of the SPOA1 and SPOA2 thumbs relative to the
thumb positions in the homodimer (orange arrows). The maximum displacement
in the fingers region of SPOA2 is highlighted in red.
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Figure 2.14: Structure of the SpaO SPOA1-SPOA2 interaction.

65

Figure 2.15: NOESY data support a SPOA1-SPOA2 interaction. (A)
Schematic illustration of the SPOA1-SPOA2 crystal structure with regions for
further analysis indicated. (B) Protons were modeled on the SPOA1-SPOA2
structure using ReadySet in Phenix. Inter-proton distances are specified for
selected inter-domain long-range amide proton correlations observed in the

15N-

NOESY-HSQC spectrum. (C-E) Protonated backbone models for the regions
specified in (A) are shown at left with residues of interest noted. In the

15N-

NOESY-HSQC spectra at right, the diagonal-peaks are indicated by red asterisks
and the cross-peaks by red dotted lines.
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Figure 2.15: NOESY data support a SPOA1-SPOA2 interaction.
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2.5 Do SPOA1-SPOA2 interactions facilitate SpaO oligomerization?
The structural characterization of the SPOA1-SPOA2 interaction suggests a
potential mechanism for the higher order assembly of a high molecular weight
sorting platform: interacting protein regions covalently linked in a polypeptide
chain can interact in cis (and remain monomeric) or can form higher order
oligomers by interacting in trans (Figure 2.16). Given the less than 20 residue
linker connecting SPOA1 and SPOA2, they would experience a low millimolarrange relative concentration and would likely interact in an intramolecular
fashion. However, at high local SpaO concentrations in association with the
T3SS, intermolecular heterotypic SPOA interactions might dominate, perhaps
forming fibrils or annuli and explaining the apparent oligomeric nature of the
sorting platform. Indeed, a similar model of intermolecular domain swapping was
recently suggested for the ring-forming injectisome protein PrgK (45).
Hypothetical SpaO oligomerization driven by intermolecular heterotypic
SPOA interactions would be dependent on the covalent linkage of SPOA1 and
SPOA2. Dynamic light scattering analysis of co-refolded SPOA1 and SPOA2
revealed a hydrodynamic radius (22 Å ± 1 Å) and predicted molecular weight (21
kDa ± 3 kDa) most consistent with a single heterodimer (expected molecular
weight: 16 kDa), as would be expected in the absence of a covalent linker
(Figure 2.16). Similarly, even at 1mM concentration, SpaO(140-297) was
monodispersed and non-oligomeric (hydrodynamic radius: 24 Å ± 1 Å; calculated
mass: 26 kDa ± 3 kDa; expected mass: 18 kDa), suggesting that the presence of
the linker does not promote intermolecular SPOA-SPOA interactions and
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oligomerization (Figure 2.16). The small increase in hydrodynamic radius relative
to co-refolded SPOA1-SPOA2 is most likely the result of the unstructured linker
projecting from the globular core, and is not consistent with high-order
oligomerization, where one would expect a very large increase in hydrodynamic
radius and calculated molecular weight. This finding is also consistent with the
size exclusion chromatography profile of SpaO(140-297), which shows a lack of
aggregation (Figure 2.9).

Figure 2.16: Hypothetical models of SPOA interactions in cis and trans. (A)
Schematic models for putative intra- and intermolecular SPOA1-SPOA2
interactions and their implications for the SpaO oligomerization state. 1 and 2
indicate the SpaO SPOA1 and SPOA2, respectively, and N indicates the SpaO
amino-terminal domain(s). (B) DLS analysis of SPOA1-SPOA2 with (right) and
without (left) the inter-SPOA linker. Regularization graph shown.
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However, one might counter that perhaps some in vivo factor promotes
intermolecular SPOA-SPOA interactions (e.g. association with the T3SS basal
body or export apparatus). Thus, I tested whether genomic deletion of the SpaO
amino-terminal domain and SPOA1 can be complemented in trans, as assayed
by S. typhimurium T3SS secretory function. When grown under T3SS stimulating
conditions, the culture supernatant of S. typhimurium has a stereotyped protein
composition, consisting of both flagellar and injectisome secretion substrates
(Figure 2.17; secreted proteins are annotated as per Aizawa and colleagues
(87)). Deletion of spaO results specifically in the loss of injectisome-dependent
secretory products from the culture supernatant, and deletion of spaO codons
1-203 phenocopies spaO deletion, indicating that the SpaO amino-terminal
domain(s) and/or SPOA1 are necessary for T3SS function (Figure 2.17).
Because SpaO(1-219) is able to complement the deletion of spaO codons 1-203
(Figure 2.17, red asterisks), the covalent linkage of SPOA1 and SPOA2 is not
necessary for T3SS function. While this does not rule out the presence of
intermolecular heterotypic SPOA interactions in vivo, if they do occur, they are
not explicitly necessary for secretion. It should be noted that SpaO(1-219) does
not complement a full genomic deletion of spaO, demonstrating that SPOA2 is
also necessary for T3SS function (Figure 2.17). Similarly, insertion of a double
stop codon after spaO codon 219 abrogates T3SS (Figure 2.17). The successful
expression of all SpaO genomic domain deletions and complementation
plasmids was confirmed by western blot (Figure 2.18).
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Figure 2.17: Covalent linkage of SPOA1 and SPOA2 is not necessary for
T3SS function. (A) Coomassie-stained SDS-PAGE of S. typhimurium culture
supernatants grown under T3SS stimulating conditions (0.3M NaCl, strain
SB1741). Bands previously identified by Aizawa and colleagues (87) are noted
and color-coded by T3SS subtype – injectisome in red, flagellar in blue. (B)
Coomassie-stained SDS-PAGE of S. typhimurium culture supernatants grown
under T3SS stimulating conditions. Red asterisks indicate injectisome-specific
secretion substrates. Abbreviations: WT, wild-type; ΔO, deletion of spaO;
Δ1-203, deletion of spaO codons 1-203; 1-219, complementation with
SpaO(1-219); 1-219stop, insertion of two stop codons following spaO codon 219.
SpaO was 3xFLAG tagged at its amino terminus in each S. typhimurium strain
(except ΔO) and complementation construct. The first two lanes of (A) and (B)
are from the same image, truncated in (A) to allow annotation.
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Figure 2.18: SpaO deletion mutants and complementation plasmids. (A, B)
Anti-FLAG western blots of SDS-PAGE separated S. typhimurium whole cell
lysates. (A) Strains carrying amino-terminal 3xFLAG fusions to SpaO with the
indicated stop codon insertions or domain deletions. ∆O denotes a strain carrying
a full deletion of SpaO, which lacks a 3xFLAG insertion and serves as a negative
control. (B) ∆O strain complemented with the indicated SpaO expression
plasmids. All expression constructs are amino-terminal 3xFLAG fusions.
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CHAPTER 3:
SpaO SPOA1-SPOA2 FORMS A PLATFORM FOR THE OrgB APAR

If heterotypic SPOA1-SPOA2 interactions do not function to create higher order
SpaO oligomers, what might be the function of this novel type of SPOA-SPOA
interaction? I hypothesized that this interaction might function in sorting platform
assembly by interacting with other sorting platform components. This chapter
describes the identification and structural characterization of a binding partner for
SpaO SPOA1-SPOA2.

3.1 Partial reconstitution of the SPI-1 sorting platform
Seminal work by Galán and colleagues (129) combined co-immunoaffinity
purification of SpaO and its binding partners from S. typhimurium with mass
spectrometric proteomic analysis to identify the majority constituents of the SPI-1
T3SS sorting platform. The proteins InvC (SctN, ATPase), OrgB (SctL, “ATPase
regulator”), and OrgA (SctK, function unknown) robustly co-purified with SpaO. To
probe these interactions more precisely, I attempted to reconstitute the core
sorting platform by heterologous coexpression in E. coli.
Double hexahistidine-tagged SpaO is able to co-affinity purify the sorting
platform components OrgB and InvC when co-expressed in E. coli (Figure 3.1A).
Formation of the SpaO-OrgB-InvC termary complex is OrgB-dependent, as SpaO
alone is insufficient to co-affinity purify InvC (Figure 3.1A). In fact, SpaO interacts
directly with OrgB, as InvC is dispensible for SpaO-OrgB complex formation
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(Figure 3.1B). Expression of the cryptically translated SpaO carboxy-terminal
fragment is not necessary for SpaO-OrgB interaction, as SpaO(ValGTT203) was
sufficient to co-affinity purify OrgB (Figure 3.1B). Interestingly, as with full length
SpaO alone, loss of the free, SPOA2-containing carboxy-terminal fragment
resulted in substantially lower soluble yields.

Figure 3.1: SpaO interacts directly with OrgB to form a SpaO-OrgB-InvC
ternary complex. (A) Coomassie-stained gel of protein elution from NiNTA resin
(top) following coexpression of double hexahistidine (12HIS)-tagged SpaO (“FL,”
full length) or SpaO(140-297, ValGTT203) with the indicated sorting platform
constituents (InvC and/or OrgB). Below, whole cell lysates from the same
preparations allow confirmation of the intended constituents’ expression. Asterisk
denotes nonspecific co-purifying E. coli proteins, likely chaperones. SpaOc
indicates the cryptically expressed SPOA2-containing carboxy-terminal fragment.
(B) Coomassie-stained gel of protein elution from NiNTA resin (top) following
coexpression of OrgB and double hexahistidine (12HIS)-tagged, full length SpaO
with the indicated codon 203 genotype. Below, whole cell lysates from the same
preparations allow confirmation of the intended constituents’ expression. Asterisk
denotes nonspecific co-purifying E. coli proteins, likely chaperones. SpaOc
indicates the cryptically expressed SPOA2-containing carboxy-terminal fragment.
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Figure 3.1: SpaO interacts directly with OrgB to form a SpaO-OrgB-InvC
ternary complex.
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Coexpression of double hexahistidine-tagged SpaO with OrgA did not result in
co-affinity purification of the two species and presumptive OrgA expression was
particularly low (Figure 3.2A). Additional coexpression of InvC or InvC-OrgB did
not enhance OrgA expression levels or result in co-affinity purification of OrgA
(Figure 3.2B). OrgA could be robustly expressed in E. coli as a double
hexahistidine fusion and purified under denaturing conditions (Figure 3.2C), but
could not be solubly refolded.

Figure 3.2: Attempts to incorporate OrgA into SpaO containing complexes
were unsuccessful. (A) Coomassie-stained gel of protein elution from NiNTA
resin (left) following coexpression of double hexahistidine (12HIS)-tagged SpaO
with the indicated sorting platform constituents (InvC and/or OrgA). At right,
whole cell lysates from the same preparations allow confirmation of the intended
constituents’ expression. SpaOc indicates the cryptically expressed SPOA2containing carboxy-terminal fragment. (B) Coomassie-stained gel of protein
elution from NiNTA resin (left) following coexpression of double hexahistidine
(12HIS)-tagged InvC with the indicated sorting platform constituents. At right,
whole cell lysates from the same preparations allow confirmation of the intended
constituents’ expression. Red asterisk denotes presumptive OrgA expression. (C)
OrgA can be robustly overexpressed in E. coli as a double hexahistidine fusion,
but it is not soluble when purified under native conditions. L, ladder; WCL, whole
cell lysate; E, NiNTA elution after purification under native conditions; UE, NiNTA
elution after purification under denaturing conditions.
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Figure 3.2: Attempts to incorporate OrgA into SpaO containing complexes
were unsuccessful.
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Given the biochemical intractability of OrgA, I decided to focus my efforts on the
SpaO-OrgB-InvC subset of the sorting platform. I hypothesized that the SPOA1SPOA2 module might serve as a scaffold for the interaction of SpaO with OrgBInvC. Indeed, SpaO(140-297) is sufficient to co-affinity purify OrgB-InvC (Figure
3.1A). This construct also contains the ValGTT203 mutation, further demonstrating
that the SPOA2 homodimer is dispensable for SpaO-OrgB-InvC complex
formation.
OrgB and its homologues are predicted to share a common aminoterminal organization: a disordered region followed by a coiled coil (Figure 3.3A).
In the flagellar system, the unstructured region at the amino terminus of the OrgB
homologue FliH is necessary for its interaction with the SpaO homologues FliM
and FliN (133). Similarly, deletion of the pre-coiled-coil residues (1-30) of OrgB
prevented the formation of the SpaO-OrgB-InvC ternary complex (Figure 3.3B).
Of note, these residues were dispensable for the interaction of OrgB with InvC
(Figure 3.3B), consistent with the work of Dr. Mirjana Lilic (Laboratory of
Structural Microbiology, Rockefeller University) and previously published yeast
two hybrid data from Shigella (182). The amino-terminal 30 residues of OrgB
were by themselves sufficient to interact with SPOA1-SPOA2 of SpaO.
OrgB(1-30) could be expressed as a fusion to human thioredoxin and co-refolded
with SpaO(140-297). After cleavage of the thioredoxin carrier from the OrgB
peptide, OrgB(2-30) co-eluted with SpaO(140-297) from a size exclusion column
(Figure 3.3D).
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Figure 3.3: The OrgB amino terminus is necessary and sufficient to mediate
the interaction with SpaO SPOA1-SPOA2. (A) COILS analysis of OrgB.
Likelihood of coiled coil formation is assessed by the program COILS. Different
scanning window sizes are indicated by line color: 14 residues, green; 21
residues, blue; 28 residues, red. CC indicates the presumed coiled coil region.
Asterisk highlights the region amino-terminal to the CC. (B) Coomassie-stained
gel of protein elution from NiNTA resin (top) following coexpression of double
hexahistidine (12HIS)-tagged InvC with the indicated sorting platform
constituents. FL denotes full length OrgB(1-226) and ∆30 denotes OrgB(31-226).
Below, whole cell lysates from the same preparations allow confirmation of the
intended constituents’ expression. Red asterisk denotes SpaO expression. (C)
SpaO(140-297) and Trioredoxin(Trx)::OrgB(2-30) purified under denaturing
conditions for co-refolding. (D) Co-refolded, 3C protease-cut SpaO(140-297) in
complex with OrgB(2-30) can be separated from free Trx and affinity tags by size
exclusion chromatography. RF+3C indicates co-refolded material after 3C
cleavage, but before further purification. The main size exclusion
chromatography peaks are denoted i and ii.
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Figure 3.3: The OrgB amino terminus is necessary and sufficient to mediate
the interaction with SpaO SPOA1-SPOA2.
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3.2 Structure of the SpaO(SPOA1-SPOA2)-OrgB(APAR) complex
Herein, I will refer to the SpaO-binding region at the amino terminus of OrgB and
its homologues as the Adaptor Peptide of the ATPase Regulator (APAR). What is
the structural basis for this interaction? In order to characterize the SPOA1SPOA2-APAR interaction by X-ray crystallography, I attempted to crystallize
complexes of the OrgB APAR peptide and SpaO(SPOA1-SPOA2), but they were
resistant to crystallization.
Fusion of readily crystallizable proteins to target proteins has been used to
enhance target crystallization (183), most notably in the case of T4 lysozyme
fusions to various GPCRs (184, 185). To explore whether this strategy might
promote crystallization of the SpaO-OrgB complex, I fused the pre-coiled-coil
region of OrgB (residues 1-30) to T4 lysozyme and found that it still bound to
SpaO(140-297) (Figure 3.4A). Consistent with the finding that the SPOA2
homodimer was not necessary for the SpaO-OrgB interaction, OrgB(1-30)::T4
lysozyme did not pull down SpaO SPOA2 homodimers (Figure 3.4A). The
Org(1-30)::T4 lysozyme fusion formed a complex with SpaO(145-213) +
SpaO(232-297) that was stable over size exclusion chromatography (Figure
3.4B), and this complex was subjected to crystallization screening. The
SpaO(SPOA1-SPOA2)-OrgB(APAR)::T4 lysozyme complex was crystallized, its
structure solved by molecular replacement using the SpaO(145-213) +
SpaO(232-297) model and a known T4 lysozyme model (PDB 2LZM), and the
structure refined to 2.0 Å resolution (Figure 3.5 and Table 3.1).
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Figure 3.4: Expression and purification of SpaO(145-213) + SpaO(232-297) +
OrgB(1-30)::T4lysozyme. (A) OrgB(1-30) fused to hexahistidine-tagged T4
lysozyme (APAR::T4::6HIS) was mixed with the indicated SpaO constructs and
passed over NiNTA resin. Coomassie-stained gels of the input and imidazole
elution are shown. (B) Purification of the SpaO(145-213) + SpaO(232-297) +
OrgB(1-30)::T4 lysozyme complex. OrgB(1-30)::T4 lysozyme (BT4) purified
under denaturing conditions (E) was refolded and purified by cation exchange
chromatography (i) after removal of affinity tags by 3C protease. Cation
exchange purified material was complexed with an excess of SpaO(145-213) +
SpaO(232-297) (“1” and “2”, respectively) and the ternary complex (ii) separated
from excess SpaO(145-213) + SpaO(232-297) (iii) by size exclusion
chromatography.
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Figure 3.5: Diffraction analysis of SpaO(145-213) + SpaO(232-297) +
OrgB(1-30)::T4lysozyme. (A) Crystals and (B) diffraction pattern for
SpaO(145-213) + SpaO(232-297) + OrgB(1-30)::T4lysozyme. Edge resolution for
diffraction image is indicated. (C) Stereoimage of a selected region of the 2Fo-Fc
electron density map for the 2.0 Å SpaO(145-213, cyan) + SpaO(232-297, green)
+ OrgB(1-30)::T4 lysozyme (gray) structure. The map is contoured to 1σ.
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Table 3.1: Diffraction and refinement statistics for SpaO(145-213) +
SpaO(232-297) + OrgB(1-30)::T4lysozyme.
Native

SeMet SpaO
Native OrgB::T4

4YX7

4YXA

P21

P21

Cell: a, b, c (Å)

62.092, 89.07, 62.092

62.88, 88.5, 63.32

Cell: α, β, γ (°)

90, 114.94, 90

90, 116.07, 90

Resolution (Å)

47.59–2.0 (2.05–2.0)

45.8–2.35 (2.43–2.35)

0.102 (0.530)

0.088 (0.617)

10.5 (3.2)

12.8 (2.6)

0.994 (0.828)

0.997 (0.816)

Completeness (%)

99.5 (99.8)

99.0 (99.6)

No. of reflections

41,183

25,740

5.1 (5.2)

6.6 (6.6)

0.1571/0.2096

0.1984/0.2618

5,769

4,940

5,112

4,818

0

0

657

122

33.10

46.90

39.60

45.60

Bond lengths (Å)

0.008

0.011

Bond angles (°)

1.16

1.46

[Φ,Ψ] Favored (%)

94

89

[Φ,Ψ] Allowed (%)

99.2

98.2

[Φ,Ψ] Outliers (%)

0.8

1.8

PDB ID
Space group

Data
Collection

Rmerge
I/σI
CC1/2

Redundancy
Rwork/Rfree
No. of atoms
Protein
Ligand/ion
Water
B factors: Protein
B factors: Ligand/ion
Refinement
B factors: Water
Geometry (r.m.s.d.)
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The crystallographic asymmetric unit contained two copies of the complex in
nearly identical conformations (superposed with 0.81 Å r.m.s.d., Figure 3.6), so
only one constituent complex will be described in the following analyses. A
cursory analysis of the crystal architecture highlights the importance of the
construct modifications used to enhance crystallization. Deletion of the interSPOA linker peptide appears to have allowed favorable packing within the
asymmetric unit: the two SPOA1-SPOA2 dimers pack against each other’s
“bottom” face, where the linker peptide might normally be positioned.
Furthermore, the T4 lysozyme fusion chaperones form multiple packing
interfaces with both SpaO and other T4 lysozyme molecules (Figure 3.6)
Within each constituent SpaO-OrgB complex, the OrgB APAR forms a
lariat-like structure, contacting the thumb of SPOA2 and fingers of SPOA1
(Figure 3.7). OrgB makes substantial contact with both SPOA1 and SPOA2 of
SpaO, burying 570 Å2 against SPOA1 and 470 Å2 against SPOA2, consistent
with the finding that both SPOAs are required for the SpaO-OrgB(APAR)
interaction (e.g. that SPOA2 alone is insufficient, Figure 3.4A). In the APARbound structure, there is little change in the conformation of SpaO (Figure 3.7,
1.01 Å r.m.s.d.). To confirm the crystallographic model, crystals grown with
SeMet-doped SpaO (but native OrgB::T4 lysozyme) were subjected to diffraction
analysis (Table 3.1). The structure was solved by molecular replacement using
the all-native structure and anomalous scatterer positions were determined using
ANODE (186). Six pronounced anomalous density peaks were observed in the
asymmetric unit, spatially corresponding to the three structured Met residues in
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each SPOA2 (Figure 3.8), further confirming the arrangement and stoichiometry
of SPOA domains in the structure.

Figure 3.6: Asymmetric unit and crystal packing of the SpaO(SPOASPOA2)-OrgB(APAR) complex. (A) The asymmetric unit of the SpaO(145-213,
cyan) + SpaO(232-297, green) + OrgB(1-30)::T4 lysozyme (gray) crystal contains
two copies of the SpaO-OrgB complex. (B) Superposition of the two constituent
complexes in the asymmetric unit of the crystal showing their architectural
similarity (0.81 Å r.m.s.d.). (C,D) Qualitative analysis of crystal packing reveals
that T4 lysozyme is involved in contacts with SpaO (C) and with itself (D). (C, red
dashed box) Two copies of SpaO surrounded by T4 lysozyme molecules (3
shown). (D, red dashed box) T4 lysozyme molecule sandwiched between two
other T4 lysozyme molecules.
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Figure 3.7: Crystal structure of the SpaO(SPOA1-SPOA2)-OrgB(APAR)
complex. (A) Ribbon diagram of the SpaO-OrgB crystal structure. For simplicity,
the T4 lysozyme crystallization chaperone has been omitted and only one of the
two constituent complexes from the crystallographic asymmetric unit is shown.
The amino- and carboxy-termini of the OrgB APAR are denoted as “N” and “C,”
respectively. (B) Surface representation of the complex in (A). The OrgB APAR
(gray mesh) contacts both SpaO SPOA1 (cyan) and SPOA2 (green). (C)
Superposition of the apo- (cyan/light green) and APAR-bound (blue/dark green)
forms of SpaO (1.01 Å r.m.s.d.).
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Figure 3.8: ANODE confirmation of SPOA positioning and stoichiometry in
the SpaO(SPOA1-SPOA2)-OrgB(APAR) complex. ANODE analysis of the
anomalous signal in the SpaO(SPOA1-SPOA2)-OrgB(APAR)::T4 lysozyme
complex generated by SeMet substitution in SpaO (but not OrgB::T4 lysozyme).
The anomalous signal (violet, contoured at 8 e/Å3) localizes to the three
structured SeMet in each copy of SpaO(232-297), providing empirical
confirmation of the SpaO-OrgB model coordinates and stoichiometry. The image
was created in COOT. Red crosses are structured solvent.

Independent NMR analyses of SpaO(140-297) bound to OrgB(APAR) in solution
are consistent with the interface defined in the crystal (Figure 3.9). 151 out of 155
possible amide proton resonances were assigned for APAR-bound
SpaO(140-297). Changes in amide proton chemical shift upon APAR binding
were calculated as the magnitude of weighted Euclidean vectors (see Chapter 7).
Compared to apo-SpaO, the largest chemical shift deviations (CSD) of backbone
amide resonances in SpaO-OrgB occur in two major clusters along the SpaO
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primary structure — one each in SPOA1 and SPOA2 (Figure 3.9). These
residues map on the crystal structure as a single surface patch at the SpaOOrgB interface (Figure 3.9). It should be noted that the NMR data suggest that
the inter-SPOA linker is not directly involved APAR-binding (Figure 3.9), an
assertion that was impossible to make using the linker-free crystallographic
model.
Additional NMR analyses allowed me to rule out interactions between
SpaO(SPOA1-SPOA2) and the APAR-adjacent coiled coil region of OrgB. The
HSQC of SpaO(140-297) bound to OrgB(1-70), which contains both the APAR
and coiled coil regions, was grossly similar to that of SpaO bound to the OrgB
APAR alone (Figure 3.10A), suggesting that the OrgB coiled coil does not make
additional contacts with SpaO upon APAR binding. The few differences between
the OrgB(2-30)- and OrgB(1-70)-bound SpaO HSQCs map to the region of SpaO
binding the OrgB amino terminus, which differed between these two constructs
because of divergent cloning scars (Figure 3.10B). Indeed, the HSQC of SpaO
bound to OrgB(1-70) was indistinguishable from that of SpaO bound to
OrgB(1-30) fused to an inert carrier (the cyan fluorescent protein variant
Cerulean), in which both OrgB amino-termini were identical Figure 3.10C).
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Figure 3.9: Solution NMR data support the crystallographic model of the
SpaO(SPOA1-SPOA2)-OrgB(APAR) complex. (A) Overlayed

15N-HSQC

of

apo- (green) and APAR-bound- (violet) SpaO(140-297). The five largest peak
shifts are noted. (B) Chemical shift deviations (CSD) for apo- vs. APAR-boundSpaO(140-297). Note that the unstructured linker is residues 214-231. (C) The
solution interaction data from (A, B) are mapped onto the SpaO-OrgB crystal
structure. Surface residues are color coded by the size of their weighted CSD in
units of standard deviation. Residues not assigned an amide resonance in one of
the two data sets are left white. The same view of SpaO is shown without (top)
and with (bottom) the OrgB APAR (gray surface).
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Figure 3.10: The OrgB coiled coil region does not interact with
SpaO(SPOA1-SPOA2). (A) Overlayed

15N-HSQC

of APAR-coiled-coil-bound-

(B(1-70), green) and APAR-bound- (B(2-30), violet) SpaO(140-297). (B) The 7
residues (red) with the most perturbed resonances in (A) are clustered around
the OrgB amino-terminal 5 residues (green) in the SpaO-OrgB crystal structure.
(C) The amide proton resonances of SpaO(140-297) bound to OrgB(1-30)::
Cerulean is indistinguishable from that bound to OrgB(1-70). Zoomed

15N-HSQC

highlighting concordance at HN/G200 is shown. HN/G200 was one of the 7
resonances discordant between OrgB(2-30)- and OrgB(1-70)-bound SpaO.
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The SpaO residues that make up the core of the OrgB-binding interface are
highly conserved across both the Salmonella/Shigella and Yersinia/
Pseudomonas T3SS clades (Figure 3.11A,B). In the crystal, a subset of these
residues form the hydrophobic docking site for the aliphatic side chains of OrgB
residues Ile17, Leu18, and Ile19 (Figure 3.11D). The OrgB surface area buried by
these three residues (360 Å2) accounts for approximately one third of the APAR’s
total buried area. Here, the APAR shows noteworthy sequence homology:
immediately following a conserved glycine (Gly16, pseudo-lariat apex) is a string
of aliphatic and basic amino acids in each homologue (Figure 3.11C). The
sequence conservation on both sides of the SpaO-OrgB interface suggests that
this mode of binding is generally applicable to other injectisome systems.

Figure 3.11: Generalizability of the SPOA1-SPOA2-APAR model. (A) The
SpaO residues at the APAR interaction site are highly conserved across
homologues in other species. Excerpts of the M-COFFEE alignment of SpaO, S.
flexneri Spa33, Y. enterocolica YscQ, and P. aeruginosa PscQ are shown with
conserved APAR-interacting residues highlighted in red. Asterisk denotes
identity; colon, high conservation; period, low conservation. (B) A surface
representation of SpaO with the 100% or highly conserved interfacial residues
identified in (A) colored red and the OrgB APAR backbone is yellow. (C) Clustal
Omega alignment of the APAR regions of OrgB, S. flexneri MxiN, Y. enterocolica
YscL, and P. aeruginosa PscL. Color code: Aliphatic/aromatic, black; basic, blue;
acidic, red; polar/gylcine, green. (D) The binding site for OrgB(17-19, gray) is
shown as an electrostatic surface. OrgB(1-15) have been removed for clarity.
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Figure 3.11: Generalizability of the SPOA1-SPOA2-APAR model.

To quantitatively assess the thermodynamic parameters of the SpaOOrgB(APAR) interaction, the binding of SpaO(140-297) to OrgB(1-30)::Cerulean
was probed by isothermal titration calorimetry (ITC). At 25°C, SpaO(140-297)
bound to the APAR peptide with a dissociation constant of 2.0 µM ± 0.5 µM at
1.04 ± 0.01 sites (Figure 3.12). No binding was observed between
SpaO(140-297) and Cerulean without the APAR fusion.

Providing additional

support for the necessity of SPOA1 in APAR binding, no specific binding was
observed between the SPOA2 homodimer and OrgB(1-30)::Cerulean (Figure
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3.12). The interaction between the APAR and SpaO(140-297) was endothermic
and entropy driven (∆H = 1602 ± 71 cal/mol; ∆S = 31.5 ± 0.3 cal/mol/deg),
consistent with the importance of hydrophobic interactions at the interface.

Figure 3.12: Quantitative assessment of SpaO(SPOA1-SPOA2)-OrgB(APAR)
binding thermodynamics. Representative ITC data for the OrgB APAR
interacting with SpaO SPOA1-SPOA2 (left) and SPOA2 alone (right). The
uncorrected power differential between the reference and sample cells is shown
on top; the background subtracted heats are shown on the bottom.
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3.3 SPOA-APAR interaction is necessary for T3SS function
To test whether the SPOA1-SPOA2-APAR interaction per se is necessary for
T3SS function, I sought to construct an APAR mutant that would disrupt SpaO
binding. The crystallographic model and binding thermodynamics suggested that
mutation of OrgB(17-19) from aliphatic to charged residues (I17D,L18D,I19D)
would disrupt the the SpaO-OrgB interface. As predicted, SpaO failed to coaffinity purify OrgB(I17D,L18D,I19D)-InvC when co-expressed in E. coli (Figure
3.13A). Notably, the triple mutation did not impair OrgB solubility or affect InvC
binding (Figure 3.13B). In vivo, the aspartate triple mutation completely abolished
T3SS secretory function (Figure 3.13C), consistent with the hypothesis that the
SpaO(SPOA1-SPOA2)-OrgB(APAR) interaction is necessary for T3SS function.
Fluorescence microscopic analyses of the Yersinia SpaO homologue have
shown it to localize in discrete perimembranous punctae (137). Might the
SPOA1-SPOA2-APAR interaction function to localize SpaO to the bacterial inner
membrane? In an otherwise wild-type genomic background, an EGFP::
3xFLAG::SpaO fusion exhibits punctate, perimembranous localization, consistent
with its recruitment to injectisome basal body channels (Figure 3.13D). Deletion
of orgB disrupts proper SpaO localization, producing a more diffuse, cytoplasmic
pattern, and the asparate triple mutation was sufficient to phenocopy the orgB
deletion mutant (Figure 3.13D). Together, these data suggest that the SPOA1SPOA2-APAR assembly is necessary for the proper localization of SpaO to
discrete perimembranous puncta, and that this arrangement is required for T3SS
function.
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Figure 3.13: Structure based disruption of the SpaO(SPOA1-SPOA2)OrgB(APAR) interaction disrupts T3SS function and SpaO subcellular
localization. (A) Co-affinity purification of double hexahistidine-tagged SpaO
with InvC and OrgB (WT, wildtype; 3xD, I17D/L18D/I19D) coexpressed in E. coli.
Coomassie-stained gel is shown. Asterisk denotes nonspecific co-purifying E. coli
proteins, likely chaperones. SpaOc indicates the cryptically expressed SPOA2containing carboxy-terminal fragment. (B) Co-affinity purification of double
hexahistidine-tagged InvC and 3xD OrgB. (C) Coomassie-stained culture
supernatant from wild-type (WT, strain SB1741), orgB deletion(Δ) and
orgB(I17D,L18D,I19D) (3xD) S. typhimurium shows loss of injectisome substrate
(red asterisks) secretion in the mutants, while flagellar secretion remains intact.
(D) Widefield microscopic imaging of fixed S. typhimurium shows exclusive
perimembranous localization of EGFP::3xFLAG::SpaO in the wild type
background but cytoplasmic localization in the orgB mutants (scale bar is 2 µm,
single z-slices shown). Nile red is used as a membrane stain.
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Studies of the flagellar apparatus suggest an intriguing alternate function for the
APAR region of OrgB. In the flagellar system, the extreme amino terminus of the
OrgB homologue FliH has been shown to be necessary for proper localization of
the FliH-FliI (InvC homologue) complex to the flagellar T3SS export apparatus
(133). Photocrosslinking studies place the FliH amino terminus in close proximity
to the export apparatus protein FlhA (InvA homologue), but evidence for a direct
interaction is weak (187). Might the APAR of OrgB interact with the cytoplasmic
domain of InvA? One might imagine a scenario where APARs extending from
OrgB-InvC complexes are able to interact with both SpaO and InvA, bridging the
sorting platform and export apparatus. However, while double hexahistidinetagged SpaO(140-297) could co-affinity purify OrgB(1-30)::Cerulean, no
interaction between double hexahistidine tagged InvA(cytoplasmic domain) and
OrgB(1-30)::Cerulean was observed (Figure 3.14).

Figure 3.14: The OrgB APAR does not interact with the InvA cytoplasmic
domain. Co-affinity purification of OrgB(1-30)::Cerulean with the indicated
double hexahistidine tagged proteins shows that the OrgB APAR does not
interact with the cytoplasmic domain of InvA in isolation.
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CHAPTER 4:
SPOA-APAR INTERACTIONS IN THE FLAGELLAR T3SS

4.1 SPOA-APAR interactions are T3SS subtype specific
As described above, S. typhimurium contains three T3SS: two injectisomes and a
flagellar apparatus. The flagellar structural analog of the the sorting platform is a
robust annulus of density at the cytoplasmic face of the flagellar basal body. This
“C-ring” is primarily composed of three proteins: FliM, FliN, and FliG (188). The
SpaO homologues FliM and FliN are predicted to contain one SPOA domain
each, which I prospectively designate as SPOA1 and SPOA2, respectively
(Figure 4.1). Paralleling the injectisome, FliN is known to interact with the OrgB
homologue FliH (133). The evolutionary relationship between injectisomes and
flagella creates a practical conundrum: how are homologous T3SS components
segregated to their corresponding secretion systems within a common
cytoplasmic milieu?
To qualitatively assess the subtype specificity of SPOA-APAR interactions,
I co-affinity purified a panel of Salmonella SPOA domains with hexahistidinetagged APAR::T4 lysozyme fusions (Figure 4.2). Indeed, the OrgB and FliH
APARs robustly co-affinity purify their cognate SPOA1-SPOA2 proteins but not
that of the other T3SS subtype (Figure 4.2). Neither SpaO nor FliM-FliN are
pulled down by the APAR from a second pathogenic T3SS found in S.
typhimurium (SPI-2 SsaK).
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Figure 4.1: SPOA domains in the S. typhimurium genome. Prospective
annotation of the six SPOA domains in the S. typhimurium genome based on the
SpaO structures presented here and those of its injectisome and flagellar
homologues. Note that the prediction of an internal translation start site at M217
in SsaQ is based on the work of Ghosh and colleagues (141). FliM and FliN are
expressed from tandem open reading frames in the same operon.
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Figure 4.2: SPOA-APAR interactions are T3SS subtype specific. Coomassiestained gels showing the input and imidazole elution for APAR-SPOA co-affinity
purification experiments. Red asterisks indicate the cognate SPOA1-SPOA2
band(s). Abbreviations: T4lyso: T4 lysozyme; O1,2: SpaO(140-297); O2:
SpaO(232-297); M: FliM(245-320); N: FliN (1-137); n: co-purifying amino-terminal
FliN degradation product.
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4.2 Structural basis for the interaction of FliM(SPOA) with FliN(SPOA)
I hypothesized that divergence of the SPOA1-SPOA2-APAR assembly
architecture contributes to proper component segregation among T3SS
subtypes, and sought to structurally characterize the flagellar SPOA-APAR
interactions. While complexes of the FliM SPOA and FliN were stable, they were
resistant to crystallization. Interestingly, FliM and FliN can be fused and still
support flagellin secretion (Figure 4.3) and some swarming motility (189). In a
sense, such FliM-FliN fusions are analogous to SpaO(ValGTT203), in that a single
polypeptide contains both SPOA domains and no free SPOA2 is produced.
A construct containing the SPOA of FliM (residues 245-334) fused to
FliN(5-137) was expressed in E. coli and purified by anion exchange and size
exclusion chromatography (Figure 4.3). This construct readily crystallized, and
SeMet-doped material gave rise to crystals with diffraction characteristics
superior to native protein. The FliM(245-334)::FliN(5-137) structure was solved
by SeMet SAD and refined to 2.56 Å using the SeMet data set (Figure 4.4 and
Table 4.1).
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Figure 4.3: Expression, purification, and function of FliM-FliN fusion
protein. (A) FliM-FliN fusion is compatible with flagellar secretory function.
Coomassie-stained PAGE of culture supernatants from S. typhimurium with the
indicated genotype (WT, wild-type; ΔMN, deletion of fliM and fliN; M::N, FliMFliN(5-137) fusion). Flagellar specific secretory products (lost in the fliM/fliN
deletion background) are present in the FliM-FliN fusion strain (blue asterisks
highlight FliC and FlgL). The FliM::FliN fusion brings FliN residue 5 in frame with
full-length FliM; both Met1 and Met4 of FliN are deleted to prevent spurious
translation of free FliN. (B-D) Purification of FliM(245-334)::FliN(5-137). NiNTA
purified protein (“E”) was cut with 3C and subjected to anion exchange
chromatography (B). The main peaks (i) were then further purified by size
exclusion chromatography (C), peak (ii). (D) Coomassie-stained gel of E, i, ii.
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Figure 4.4: Diffraction analysis of FliM(245-334)::FliN(5-137). (A) Crystals and
(B) diffraction image of the FliM-FliN fusion protein (SeMet incorporated). (C)
Stereoimage of a selected region of the 2Fo-Fc electron density map for the 2.56
Å FliM(245-334, cyan)::FliN(5-137, green) structure. The map is contoured to 1σ.
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Table 4.1: Diffraction and refinement statistics for FliM(245-334)::
FliN(5-137).
SeMet
PDB ID

4YXB

Space group

Data
Collection

P212121

Cell: a, b, c (Å)

75.15, 81.50, 89.96

Cell: α, β, γ (°)

90, 90, 90

Resolution (Å)

57.67–2.56 (2.67–2.56)

Rmerge

0.097 (1.215)

I/σI

18.5 (2.7)

CC1/2

0.999 (0.814)

Completeness (%)

100 (100)

No. of reflections

18,372

Redundancy

13.8 (14.3)

Rwork/Rfree

0.2175/0.2593

No. of atoms

2,633
Protein

Refinement

2,605

Ligand/ion

5

Water

23

B factors: Protein

68.30

B factors: Ligand/ion

73.40

B factors: Water

64.50

Geometry (r.m.s.d.)
Bond lengths (Å)

0.010

Bond angles (°)

1.31

[Φ,Ψ] Favored (%)

92

[Φ,Ψ] Allowed (%)

99.1

[Φ,Ψ] Outliers (%)

0.9
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In the FliM(245-334)::FliN(5-137) structure, only the SPOA domains were clearly
structured (FliM: 258-330; FliN: 53-137). Architecturally, the FliM(SPOA1)FliN(SPOA2) interaction is similar to that of SpaO (Figure 4.5, 2.28 Å RMSD),
with the exception of additional helices present at the carboxy terminus of each
SPOA, as observed in FliN homodimers from Thermotoga maritima (139).
Additional weak density was observed in contact with the surface of the SPOASPOA structure that was strong enough in segments to be modeled as peptide. I
hypothesize that this additional density corresponds to the ~50 residues at the
amino terminus of FliN linking the two SPOA domains in this artificial fusion.
While it is tempting to speculate that these contacts are physiologically
significant, it has not yet been determined that they are anything other than an
artifact of the fusion strategy and/or crystal packing and thus will not be
discussed further here.

Figure 4.5: Structure of FliM(SPOA)-FliN(SPOA). (A) Asymmetric unit of the
FliM(245-334, cyan)::FliN(5-137, green) crystal. Noncontiguous modeled peptide
fragments are shown in gray. (B) Superposition of the two constituents of the
asymmetric unit (0.56 Å r.m.s.d) reveals a stereotypical SPOA-SPOA interaction.
(C) The topology diagram is consistent with a bona fide SPOA fold for both FliM
and FliN. (D) Superposition of apo-SpaO SPOA1-SPOA2 (light blue and green,
respectively) with apo-FliM::FliN (dark blue and green, respectively; 2.28 Å
r.m.s.d.).
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Figure 4.5: Structure of FliM(SPOA)-FliN(SPOA).

The FliM(245-334)::FliN(5-137) fusion protein eluted from size exclusion
chromatography as a much larger particle than would be expected for a
monomer of its size (Figure 4.3). Dynamic light scattering analysis of gel filtration
purified protein suggested the presence of a relatively monodispersed entity with
a 36 Å ± 1 Å hydrodynamic radius and a predicted molecular mass of 65 kDa ± 3
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kDa (Figure 4.6). Interestingly, the crystallographic asymmetric unit contained a
dimer of fusion proteins with a diameter of 50-55 Å (mass: 50 kDa; Figure 4.5).
Previous studies have noted the ability of FliN to tetramerize into a similar
doughnut-like annulus (139) and have speculatively assigned this structure to the
distal cytoplasmic aspect of the C-ring cryo-EM density, because of its quasitoroid appearance. I posit that while neither the FliN homotetramer nor FliM-FliN
heterotetramers (FliM2-FliN2 or FliM-FliN3) can be definitively ascribed to the
density in question using the data available, the FliM-FliN heterotetramers should
be considered alongside the FliN homotetramer as a candidate for the
composition of this structure.

Figure 4.6: Solution behavior of FliM(245-334)::FliN(5-137). The data for 40
µM protein is shown in the autocorrelation and regularization graphs. In the
autocorrelation graph, the raw data is shown in blue and the regularization fit is
shown in violet.
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4.3 Structure of the FliM(SPOA)-FliN(SPOA)-FliH(APAR) complex
The similarity of the SpaO and FliM/FliN SPOA1-SPOA2 structures is consistent
with a model for SPOA1-SPOA2 interactions being generalizable across T3SS
subtypes. Is the mechanism of APAR binding also structurally similar across
T3SS subtypes?
To elucidate the mechanism of FliH-specific assembly with FliM-FliN, I
sought to co-crystalize the SPOAs of FliM and FliN in complex with the FliH
APAR as a T4 lysozyme fusion. FliM(245-320), FliN(1-137), and FliH(1-43)::T4
lysozyme formed a stable complex over size exclusion chromatography (Figure
4.7); however this complex was resistant to crystallization. As one would predict
from the FliM-FliN fusion protein’s function in vivo, FliM(245-334)::FliN(5-137)
was able to bind the FliH APAR (residues 1-43) fused to lysozyme (Figure 4.7).
The APAR construct fused to lysozyme was further truncated to residues 1-18,
which still formed a complex with FliM(245-334)::FliN(5-137) (Figure 4.8). This
complex crystallized, its structure was solved to 2.30 Å resolution by molecular
replacement using the FliM(245-334)::FliN(5-137) model and T4 lysozyme
(Figure 4.9, Table 4.2)
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Figure 4.7: FliM-FliN-FliH complexes. (A) Separation of excess FliH(1-43)::T4
lysozyme fusion from the FliM-FliN-FliH::T4 lysozyme complex by size exclusion
chromatography. (B) Co-affinity purification of FliM(245-334)::FliN(5-137) with
hexahistidine-tagged FliH(1-43)::T4 lysozyme over NiNTA resin. Gels in (A) and
(B) are coomassie-stained.

Figure 4.8: Expression and purification of FliM(245-334)::FliN(5-137) +
FliH(1-18)::T4 lysozyme. FliH(1-18)::T4 lysozyme fusion (H::T4) was purified
under denaturing conditions (E), refolded, and affinity tags were removed with 3C
protease. Cleaved protein was further purified by cation-exchange
chromatography (A), mixed with FliM(245-334)::FliN(5-137) (M::N), and excess
H::T4 (iii) was separated from the complex (ii) by gel filtration chromatography
(B). Inset, Coomassie-stained gel of E and the main chromatography peaks.
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Figure 4.9: Diffraction analysis of FliM(245-334)::FliN(5-137) +
FliH(1-18)::T4lysozyme. (A) Representative crystals and (B) diffraction pattern
for the FliM(245-334)::FliN(5-137) + FliH(1-18)::T4 lysozyme complex. (C)
Stereoimage of the 2Fo-Fc electron density map for the 2.30 Å FliM(245-334,
cyan)::FliN(5-137, green) + FliH(1-18)::T4 lysozyme (gray) structure. The map is
contoured to 1σ and highlights the FliH W7 binding region.

110

Table 4.2: Diffraction and refinement statistics for FliM(245-334)::FliN(5-137)
+ FliH(1-18)::T4lysozyme.
Native
PDB ID

4YXC

Space group

Data
Collection

P212121

Cell: a, b, c (Å)

43.21, 76.37, 119.4

Cell: α, β, γ (°)

90, 90, 90

Resolution (Å)

64.33–2.30 (2.38–2.30)

Rmerge

0.070 (0.923)

I/σI

20.2 (2.6)

CC1/2

0.999 (0.811)

Completeness (%)

99.8 (99.8)

No. of reflections

18,174

Redundancy

12.9 (12.9)

Rwork/Rfree

0.1967/0.2620

No. of atoms

2,739
Protein

2,668

Ligand/ion

0

Water

71

B factors: Protein

69.70

B factors: Ligand/ion
Refinement
B factors: Water

65.00

Geometry (r.m.s.d.)
Bond lengths (Å)

0.009

Bond angles (°)

1.15

[Φ,Ψ] Favored (%)

94

[Φ,Ψ] Allowed (%)

99.1

[Φ,Ψ] Outliers (%)

0.9
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As with its injectisome counterparts, the FliM-FliN SPOA1-SPOA2 did not
undergo large conformational changes upon APAR binding (Figure 4.10B, 1.11 Å
r.m.s.d.); however, the binding mode for the FliH APAR is radically different. In
contrast to the OrgB pseudo-lariat, the FliH APAR adopts a near-linear
conformation along the “top” of FliM-FliN (Figure 4.10C). As observed in the
SpaO-OrgB assembly, the FliH APAR makes extensive contact with both SPOA1
and SPOA2 (Figure 4.10C), supporting the observation that the FliH APAR
interacts more strongly with the FliM-FliN heterodimer than the FliN homodimer
(Figure 4.2).
The FliM-FliN-FliH assembly is characterized by the burial of several
highly conserved hydrophobic FliH side-chains. Two tryptophan side-chains form
an aromatic “clamp,” which binds hydrophobic pockets on opposite faces of the
FliN thumb (Figure 4.10D). Alanine scanning mutagenesis of the FliH amino
terminus had previously identified these tryptophans as critical for flagellar
function (133), and they are highly conserved (Figure 4.10). Similarly, the bulky
side-chain of FliH Leu15 fills a hydrophobic pocket on the thumb of FliM (Figure
4.11). The binding interfaces for these three residues are formed by both FliM
and FliN and are highly conserved across species (Figure 4.11E). This structure
presents a conserved model for FliH-FliM-FliN interaction, which is distinct from
that of SpaO-OrgB.
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Figure 4.10: Structure of the FliM(SPOA)-FliN(SPOA)-FliH(APAR) complex.
(A) The crystallographic asymmetric unit for FliM(245-334, cyan)::FliN(5-137,
green) + FliH(1-18)::T4 lysozyme (gray). (B) Superposition of apo- (cyan/green)
and APAR-bound (blue/dark green) FliM::FliN (1.11 Å r.m.s.d.). (C) Ribbon
diagram (left) and surface representation (right) of the FliM-FliN-FliH structure. T4
lysozyme has been omitted. N and C indicate the amino- and carboxy-termini of
the FliH APAR, respectively. (D) A zoomed view of the FliH aromatic clamp, with
the side-chain atoms of FliH W7 and W10 represented as spheres. (E) Excerpted
M-COFFEE alignment of FliH with its homologues from S. flexneri, Y.
enterocolica, and P. aeruginosa. Highly conserved residues of interest are noted
(S. typhimurium numbering shown).
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Figure 4.10: Structure of the FliM(SPOA)-FliN(SPOA)-FliH(APAR) complex.
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Figure 4.11: Surface characteristics of the FliH(APAR) binding site. The
binding pockets for FliH W7, W10, and L15 on FliM-FliN are shown as surface
renderings. On the left, the surface is color coded by residue conservation across
S. typhimurium, S. flexneri, Y. enterocolica, and P. aeruginosa. Red indicates
100% identity. Orange, yellow, and white indicate high, medium, and low
conservation by M-COFFEE multiple sequence alignment. In the middle, the
same surface is shown but color-coded by chain: FliM is cyan, FliN is light green.
On the right, the surface is color coded by electrostatic potential (red, negative;
blue, positive).
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CHAPTER 5:
THE SpaO AMINO-TERMINAL DOMAIN

The preceding chapters have presented structures for SPOA1-SPOA2 and
SPOA2-SPOA2 complexes. In the case of the former, this architecture is
conserved from injectisomes to the flagellar apparatus and functions as a
scaffold for the SctL/FliH APAR. What, though, is the function of the SPOA2
homodimer? Similarly, my structural dissection of SpaO and its homologues has
thus far neglected its 140 amino-terminal residues: what might be their structure
and function?
In Chapter 2, I presented data showing that free SPOA2 binds to full
length SpaO and remains as a complex through purification (Figures 2.1 and
2.2). Thus, I hypothesized that free SPOA2 might be able to interact with either
the SPOA1-SPOA2 complex (residues 140-297) or with the SpaO NTD in
isolation. To test the former possibility, SpaO(140-297) was mixed with
SpaO(232-297) and passed over a size exclusion chromatography column.
There was no shift in elution volume for either component, indicating a lack of
complex formation (Figure 5.1A).
The amino-terminal domain (NTD) of SpaO is necessary for T3SS, as its
genomic deletion completely disrupts secretory function (Figure 5.1B). While
T3SS function is fully complemented by SpaO(1-303) in this mutant, it is only
partially complemented by the deleted domain (residues 1-140) (Figure 5.1B).
While secretion of some substrates is clearly restored (orange asterisk in Figure
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5.1B), secretion of other substrates is only partially restored (purple asterisks) or
is not restored at all (green asterisk), suggesting that full SpaO NTD function
requires covalent linkage to SPOA1-SPOA2. While biochemical analysis or
(ideally) structure determination might shed light on the intriguing function of the
NTD, such efforts have been impeded by its poor solubility. Inspired by my
success at producing the OrgB and FliH APAR peptides as T4 lysozyme fusions,
I fused SpaO(1-142) to lysozyme and found that the fusion protein could be
solubly refolded (Figure 5.1C). In contrast to SPOA1-SPOA2, the SpaO NTD::T4
lysozyme construct interacted with free SPOA2, as determined by co-affinity
purification (Figure 5.1D).

Figure 5.1: The SpaO NTD interacts with SPOA2. (A) Mixing SpaO(140-297)
with SpaO(232-297) does not result in a complex with a smaller elution volume
on size exclusion chromatography. (B) Coomassie-stained SDS-PAGE of S.
typhimurium culture supernatants grown under T3SS stimulating conditions.
Abbreviations: FL, full length SpaO; ΔO, deletion of spaO; Δ1-140, deletion of
spaO codons 1-140; 1-140, complementation with SpaO(1-140). SpaO was
3xFLAG tagged at its amino terminus in each S. typhimurium strain (except ΔO)
and complementation construct. Asterisks highlight bands of interest, as
described in the text. (C) Size exclusion chromatography of refolded
SpaO(1-142)::T4 lysozyme is consistent with a monodispersed sample. (D) Coaffinity purification of SpaO(1-142)::T4 lysozyme with double hexahistidine
tagged SpaO(SPOA2) is robust and substantially greater than background
binding of SpaO(1-142)::T4 lysozyme to NiNTA resin in the absence of a
hexahistidine-tagged binding partner.
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Figure 5.1: The SpaO NTD interacts with SPOA2.
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To confirm and expand on the finding that free SPOA2 interacts with the SpaO
NTD and not SPOA1-SPOA2, these interactions (or lack thereof) were probed by
isothermal titration calorimetry (Figure 5.2). Free SPOA2 bound to
SpaO(1-142)::T4 lysozyme with a dissociation constant of 20.0 µM ± 0.22 µM at
25°C. The binding isotherm was consistent with the NTD interacting with dimeric
SPOA2, as the calculated binding stoichiometry was 1:1.05 (±0.02) when the
SPOA2 concentration was input as the concentration of SPOA2 dimers. Binding
was exothermic and completely enthalphy driven (∆H = -14500 ± 36 cal/mol; ∆S
= -27.1 ± 0.1 cal/mol/deg). No specific interaction with free SPOA2 was detected
for SpaO(140-297).
Given the interaction of SPOA2 homodimers with the SpaO NTD, I
hypothesized that the NTD might be stably co-refolded with SPOA2.

Indeed,

SpaO(1-140) could be refolded with SpaO(232-297) and the complex was stable
over size exclusion chromatography (Figure 5.3). Thus far, the complex has
resisted crystallization, but it is hoped that further screening and construct reengineering might yield diffraction quality crystals of this complex.
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Figure 5.2: Quantitative analysis of the SpaO NTD-SPOA2 interaction.
Representative ITC data for the SpaO SPOA2 interacting with the SpaO NTD
(left) and SPOA1-SPOA2 (right). The uncorrected power differential between the
reference and sample cells is shown on top; the background subtracted heats
are shown on the bottom. The concentration of SPOA2 dimers in solution was
used to calculate the molar ratio.
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Figure 5.3: The SpaO NTD co-refolds with SPOA2. A SpaO (O) NTD construct
can be purified under denaturing conditions and co-refolded with SPOA2
(denaturing NiNTA elution shown, E). After refolding and filtration (RF Super.),
soluble material was liberated from its affinity tags (12HIS) by 3C protease and
soluble aggregate (uncleaved, i) separated from the NTD-SPOA2 complex (ii).
Some excess free SPOA2 remained as a chromatographic shoulder (iii).
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CHAPTER 6:
CONCLUSIONS AND FUTURE DIRECTIONS

6.1 SPOA domain structure
I have presented here a series of structures and supporting biochemical and cell
biological data that yield critical mechanistic insights into T3SS sorting platform
assembly across multiple species and secretion subtypes. The existence of
heterotypic SPOA interactions provides a structural explanation for the previously
reported 1:2 stoichiometry of full length protein to free SPOA2 in SpaO
homologues (141). While two of these SPOA2 domains could be accounted for
by a homodimer interacting with full length SpaO, the conformation of the third
SPOA2 (located in the full length protein) was unclear. Previous reports had
proposed the existence of an alternate autostabilizing conformation for the third
SPOA2, wherein the fingers of the SPOA domain in the full length protein “snap
back” against its own palm to bury the surfaces located at the dimerization
interface in SPOA homodimers (141). We show here that this third SPOA2 can
be stabilized by a SPOA1-SPOA2 interaction, and that the SPOA2 homodimer
interacts with the SpaO NTD (Figure 6.1).
What might be the function of the SPOA2 homodimer-NTD interaction in
SpaO and its SctQ-family homologues? Studies in Yersinia argue that the
cryptically translated SPOA2 fragment is necessary for T3SS function (141) and
formation of perimembranous SctQ-containing puncta (137). However,
preliminary data and communications with others in the field indicate that this is
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not the case in S. typhimurium. Perhaps the SPOA2 homodimer functions as a
chaperone, stabilizing the SpaO NTD until it can interact with some components
of the T3SS basal body or export gate. This would be consistent with the marked
decrease in solubility of full length SpaO when the internal translation start site is
mutated (Figures 2.1, 3.1), and might explain why the SPOA2 homodimer is
unnecessary for T3SS function under the “forcing” conditions of high salt
stimulation. Further biochemical analysis of the SctQ NTD and its binding
partners is needed to address this question, and whether the SPOA2 homodimer
is necessary for S. typhimurium T3SS function under physiologic conditions (i.e.
infection) should be determined.
The ratio of FliM to FliN in situ is estimated to be 1:3 (188). In the context
of our FliM-FliN structure, this suggests a model for FliM-FliN interaction similar
to that of SpaO. FliM(SPOA1) would engage FliN(SPOA2) in a heterotypic
SPOA-SPOA interaction, much like the interaction between SPOA1 and SPOA2
in full length SpaO. Additional homodimeric FliN would interact with FliM-FliN in
an as of yet undetermined fashion, analogous to the SpaO SPOA2 homodimer
interaction with the SpaO NTD (Figure 6.1). However, several lines of evidence
suggest that FliN homo-oligomers might not interact with the regions of FliM
amino-terminal to its SPOA domain in a manner homologous to the SpaO NTD(SPOA2)2 interaction. First, the SpaO NTD and the pre-SPOA regions of FliM do
not share noteworthy sequence homology, and portions of this region of FliM are
known to interact with flagellar-specific proteins (e.g. FliG, CheY) involved in
torque generation and flagellar rotation switching (145, 146). Second, FliN homo-
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oligomers may interact with the FliM(SPOA)-FliN region instead, as co-affinity
purification of hexahistidine-tagged FliM(SPOA) with FliN results in a co-purifying
stoichiometric excess of FliN that separates from 1:1 FliM-FliN on ion-exchange
chromatography (not shown).

Moreover, reports of FliN tetramerization and

FliM:FliN ratios between 1:3 and 1:4 suggest that more complicated higher order
structures may be utilized by the flagellar apparatus (139).

Figure 6.1: Overview of domain interactions within SPOA-containing
proteins. (A) Schematic of the domain interactions for the SctQ family prior to
this study. S indicates SPOA domains; N, the domains amino-terminal to the
SPOA; ??, uncertain targets of interaction. (B) The model in (A) requires an
autostablizing conformation of the SPOA domain, like the “snap back” model
shown here. (C) Schematic of SpaO domain interactions described in this work.
NTD, amino-terminal domain; 1, SPOA1; 2, SPOA2. (D) Schematic of FliM-FliN
domain interactions, both hypothetical and demonstrated. MNTD indicates the
regions of FliM amino-terminal to the SPOA; MS, FliM SPOA; NS, FliN SPOA.
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6.2 The SPOA-APAR interaction
The structures presented here suggest a partial model for the subtype-specific
assembly of the T3SS sorting platforms: the SPOA1-SPOA2 module within a
given T3SS subtype functions as an adaptor for the ATPase and its regulator
through interaction with the APAR peptide (Figure 6.2). It should be noted that
while previous investigations of the flagellar T3SS have focused on the
interaction between FliH and FliN specifically (133), my structures and
biochemical data show that the FliH APAR more strongly interacts with the FliMFliN complex than with FliN alone, suggesting that the FliM-FliN complex is the
physiologically relevant binding partner for FliH.
It is intriguing that disruption of the SPOA-APAR interaction prevented
membrane localization of the SpaO sorting platform. What might be the
mechanism for sorting platform targeting? One might imagine four non-mutually
exclusive scenarios in which the SPOA-APAR interaction promotes SpaO
membrane localization (ii-iv are diagrammed in Figure 6.3):
(i) InvC-OrgB has constitutive membrane localizing activity, and the SPOAAPAR interaction simply facilitates the trafficking of SpaO as inert cargo.
(ii) At baseline, the APAR binds to a region of InvC or OrgB preventing InvCOrgB from localizing to the membrane (either by direct competition for a
binding site or allosterically). SpaO binding of the APAR releases the
inhibition, allowing membrane localization of the complex.
(iii) At baseline, the SpaO NTD is sequestered by interacting with SPOA1SPOA2. Binding to the APAR releases the NTD, allowing it to interact with
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membrane lipid or injectisome-associated proteins, driving membrane
targeting.
(iv) The SPOA-APAR assembly might function as a scaffold module, inducing
proximity between sorting platform components whose interactions then
drive membrane localization.

Figure 6.2: Segregation of homologous sorting platform components by
subtype-specific SPOA-APAR interactions. Schematic illustration of the
proposed role for the SPOA1-SPOA2-APAR assembly in organizing and
localizing the T3SS sorting platforms in a subtype-specific fashion. IM indicates
the inner membrane; ONTD, the SpaO amino-terminal domain(s); 1 and 2, SpaO
SPOA1 and SPOA2; B, OrgB; H, FliH; MNTD, the FliM amino-terminal domains; M
and N, the SPOA domains of FliM and FliN; Injectisome, the membrane integral
components of the pathogenic T3SS; Flagellar BB, the flagellar basal body and
associated integral membrane components.
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Figure 6.3: Hypothetical mechanisms of sorting platform targeting to the
injectisome. Schematic representation of three hypothetical mechanisms for
SPOA-APAR interaction-induced membrane localization of the sorting platform
(ii, iii, and iv). Abbreviations are the same as in Figure 6.2, except MLD denotes
membrane localization domain. X represents some hypothetical interacting
protein or even a portion of the SpaO NTD.
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One might distinguish among these hypothetical mechanisms with a series of
genetic experiments utilizing genomic encoded GFP fusions. For example,
hypothesis (i) would predict that deletion of neither spaO nor the orgB APAR
would affect GFP::InvC localization to perimembranous puncta. However,
hypothesis (ii) would predict that deletion of spaO would impair GFP::InvC
localization to the membrane, and that phenotype would be rescued by deletion
of the orgB APAR. Both hypotheses (i) and (ii) would predict that
GFP::SpaO(SPOA1-SPOA2) would localize to the membrane in an OrgBdependent fashion, but that GFP::SpaO(NTD) would show cytoplasmic
localization. By contrast, hypothesis (iii) would predict that GFP::SpaO(NTD)
would be membrane localized, regardless of invC or orgB genotype, and that
GFP::SpaO(SPOA1-SPOA2) would be cytoplasmic. Lastly, hypothesis (iv) would
predict that both GFP::SpaO(NTD) and GFP::SpaO(SPOA1-SPOA2) would be
localized to the cytoplasm.
Hypothesis (iii) — that the SpaO NTD has membrane localizing activity
and that this activity is sequestered prior to SPOA-APAR interaction — is
particularly intriguing on several levels. First, early preliminary data suggests that
GFP::SpaO(NTD) does localize to the membrane (not shown). Second, this
hypothesis would imply a testable function for the NTD interaction with the inner
membrane or some membrane associated T3SS component (discussed further
in Section 6.3, below). Third, this hypothesis implies an interaction between the
NTD and the SPOA1-SPOA2 module prior to APAR binding. Preliminary data do
not demonstrate the existence of such an interaction when the modules are not

128

covalently linked (pull down experiments, not shown). However, in the context of
the full length protein, these domains would be constrained by their covalent
linkage, and so even low affinity, transient interactions between the domains
might be functionally relevant. Of course, capturing full length SpaO in a crystal
for diffraction analysis remains a priority for the field; however, solution NMR may
offer some insight into whether these presently hypothetical interactions exist and
are worth pursuing. For example, if the TROSY “fingerprint” for SpaO(140-297)
(Figure 2.10) is altered in the context of the full length protein, it would suggest
that the NTD makes contact with the SPOA1-SPOA2 module. In particular, one
might imagine a case where the APAR-binding region shows signs of
perturbation, consistent with some portion of the NTD docking in that site.
Regardless of the underlying mechanism, the finding that the SPOA-APAR
interaction is necessary for T3SS function makes it an interesting target for the
development of potential anti-virulence compounds. Unlike other potential antivirulence targets in the T3SS that have human homologues (e.g. the SctN
ATPase), the SPOA fold appears to be unique to the T3SS, with no reported
structures possessing this fold in other systems, raising the prospect that
therapeutics targeting this interaction could have little off-target toxicity to the
host. In particular, the high degree of sequence (and presumably structural)
conservation among the flagellar SPOA-APAR pairs suggests that it might even
be possible to target the flagellar apparatus with “broad spectrum” efficacy.
The design of therapeutics targeting the SPOA-APAR interaction would
not be without major challenges, though. While it is tempting to use the APAR
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peptide structures themselves as models for the development of “APARmimetics” that could compete with the endogenous peptide for SPOA-binding,
the relatively low affinity (Kd=2.0 µM) of the interaction is not within the
nanomolar range typically seen as attractive in a pharmacologic lead compound.
Indeed, the APAR peptides in both the SPI-1 T3SS and flagellar apparatus bind
large exposed protein surfaces, not the deep pockets that are most amenable to
tight, “lock and key” fits of small molecules.
Nonetheless, I have developed a Förster resonance energy transfer
(FRET)-based assay for the high throughput screening of small molecule
disruptors of the SPOA-APAR interaction. The architecture of the SPOA-APAR
complexes (both flagellar and SPI-1) place APAR and SPOA domain termini
within the Förster radius of the modified yellow fluorescent protein-cyan
fluorescent protein pair, Venus-Cerulean (R0=52 Å, ref. (190); Figure 6.4C,D),
suggesting that fusions to these fluorescent proteins at the indicated termini
might generate a detectable FRET signal in vitro. Carboxy-terminal fusion of
Venus to SpaO(115-297) is compatible with protein expression and soluble
purification from E. coli. In the presence of the previously characterized
OrgB(1-30)::Cerulean fusion, substantial FRET is observed (Figure 6.4A,B).
Neither fusion protein exhibits FRET in the presence of the other fluorescent
protein without the cognate interaction partner, ruling out nonspecific interactions
between either SpaO or OrgB and the fluorescent proteins as a spurious cause
of FRET (Figure 6.4B).
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Figure 6.4: A FRET-based assay for high throughput drug screening. (A)
Fluorescence emission scans of 100 µM each Cerulean and Venus (blue) or
OrgB(1-30)::Cerulean and SpaO(115-297)::Venus (orange). Excitation
wavelength fixed at 435 nm. Single asterisk highlights donor quenching, and
double asterisk highlights acceptor stimulated emission. (B) Relative FRET
efficiencies, scaled to Cerulean + Venus = 0. Abbreviations: C, Cerulean; V,
Venus; APAR::C, OrgB(1-30)::Cerulean; SpaO::V, SpaO(115-297)::Venus; C5V,
Cerulean and Venus connected by a 5 amino acid linker. Each mixture contained
100 µM of each fluor. Values are the mean of five technical replicates; error bars
are +/- the standard deviation. (C, D) Structural basis for the design of
fluorescent protein fusion FRET probes for the SPI-1 (C) and flagellar (D) SPOAAPAR interaction.
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6.3 Higher order interactions in the T3SS sorting platform
A number of questions remain regarding the higher order architecture of the
sorting platform in situ. I hypothesize that the puncta formed by SpaO in vivo
represent the high-molecular weight sorting platforms described by Galán and
colleagues (129).

Armitage and colleagues have quantified the stoichiometry

and dynamics of these puncta in Yersinia, showing them to possess ~22 copies
of YscQ (SpaO homologue) per punctum and to be in dynamic exchange with the
cytoplasm (137). In contrast, Liu and colleagues’ recent tomographic
reconstruction of Shigella injectisomes revealed the presence of only six SpaO
homologue-dependent pods of density beneath the injectisome, and their
localization was OrgB homologue-independent (128).

Taken together with my

findings, these results suggest that there may be two subpopulations of SpaO in
vivo: one stably associated with the injectisome, and a second dynamic
population in exchange with the cytoplasm, requiring the SPOA-APAR interaction
to form high molecular weight, perimembranous sorting platforms. Recent
analyses of FliI ATPase dynamics by Minamino and colleagues suggest a similar
two population model, which they hypothesize functions to deliver secretion
substrates to the assembling flagella (136).
Integrating SpaO structures into such models of sorting platform assembly
function will require further exploration of the interactions between constituents of
the large complex reported by Galán and colleagues (129). For example, the
structure of the sorting platform component OrgA remains to be determined, and
its role in platform assembly is similarly opaque. Its apparent insolubility and
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previous reports of self association in yeast two hybrid studies (182) suggest that
it may play a role in high molecular weight oligomerization of the sorting platform.
While OrgA lacks a clear flagellar homologue, the flagellar protein FliG (which
itself lacks a clear injectisome homologue) self associates to organize C-ring
assembly (191), and it is temping to speculate that these non-homologous
proteins might be functional analogues.
Similarly, the biochemical basis for sorting platform association with the
basal body (e.g. SctD), the export apparatus (SctV), and/or their associated
regulators (e.g. SctP, SctW, SctO, SctU) remains to be determined and may offer
further insights into the mechanism of sorting platform localization to the
injectisome superstructure. For example, previous work in Shigella identified a
peptide from SctQ that interacts with the cytoplasmic domain of the basal body
protein SctD (47). My structures would place this peptide in the “fingers” region of
SPOA1, a plausible site for an interaction interface. However, I have been unable
to reproduce an interaction between SpaO and PrgH (SctD) in vitro (not shown),
and others have questioned the physiologic relevance of this interaction (48).
Lastly, the implications of sorting platform assembly for substrate
recruitment, dechaperoning, and secretion remain unclear, and will require
further studies of interactions between substrate-chaperone pairs and the sorting
platform, the ATPase, and the export gate. Indeed, analysis of these complexes
may even offer insight into the recruitment of the sorting platform to the
injectisome, as interactions with substrate-chaperone pairs have been
hypothesized to bridge the sorting platform and the injectisome basal body (48).
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However, with few exceptions (125), such complexes of substrates, chaperones,
and components of the sorting platform or export apparatus have not proven
sufficiently stable for rigorous structural interrogation.
Ideally, micro-level insights from structural characterization of the
aforementioned complexes will be paralleled with improvements in the electron
microscopic (or, potentially, X-ray crystallographic) maps of the holo-injectisome
and flagellar apparatus, allowing the incorporation of precise structural details
into larger scale structural models of T3SS structure and function.

6.4 Technical considerations
The use of T4 lysozyme as a peptide stabilizing agent and crystallization
chaperone merits brief technical consideration.

For both the SpaO-OrgB and

FliM-FliN-FliH structures, T4 lysozyme fusions were used to solubilize peptides
with considerable hydrophobic character and also supplied additional
crystallogenic packing interfaces.

While T4 lysozyme fusions have received

attention for their ability to facilitate the crystallization of membrane proteins, their
applicability as general crystallization chaperones is less well studied.

Other

large protein fusions have been used to facilitate the crystallization of globular
proteins (183), and I propose that T4 lysozyme might be similarly useful.
However, I did note that the intrinsic flexibility between the amino- and carboxyterminal lobes of T4 lysozyme resulted in substantially less order in the aminoterminal lobe and model building for this region was challenging (Figure 6.5).
Kobilka and colleagues also noted this phenomenon in their G-protein coupled
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receptor::T4 lysozyme structures and have engineered T4 lysozyme variants to
overcome it (192). These re-engineered crystallization chaperones may prove
useful to the crystallization of challenging globular proteins or protein-peptide
interactions.

Figure 6.5: Disorder of the T4 lysozyme amino-terminal lobe complicates
model building. (A) Model of one T4 lysozyme molecule from the SpaO-OrgB
crystallographic asymmetric unit color coded by increasing (purple to red) Bfactor. The amino- and carboxy-terminal lobes are indicated as “NT” and “CT,”
respectively. Asterisk indicates the substrate binding pocket. (B) Comparison of
the T4 lysozyme molecules from SpaO-OrgB (blue, purple) and FliN-FliM-FliH
(pink) aligned globally. Note the greater divergence of the amino-terminal lobe
between structures (arrow).
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CHAPTER 7:
METHODS

7.1 Bioinformatics
Sequence alignments were performed using Clustal Omega (178) or M-COFFEE
(193). Secondary structure and disorder predictions were performed using the
PSIPRED server (194). Coiled coil prediction was preformed using the COILS
server (195).

7.2 Molecular biology and general microbiology
Polymerase chain reaction (PCR) was performed using OneTaq (New England
Biolabs), Phusion (New England Biolabs), or PfuTurbo (Agilent) as per
manufacturer guidelines with oligonucleotides purchased from Integrated DNA
Technologies. All mutations or gene fusions were created by overlap extension
PCR. Gene sequences from S. typhimurium were PCR amplified from the T3SScompetent strains SB300 (wild-type; gift of J. Galán) or SB1741 (3xFLAG::SpaO,
silent SpaO L79CTG to L79CTA variant; gift of J. Galán) (129). The T4 lysozyme
(C54T, C97A) sequence was obtained from Addgene plasmid 18111. An
additional mutation (D20N) in T4 lysozyme was made to decrease toxicity in E.
coli (196), and the terminal three residues were mutated to alanines to decrease
conformational entropy.
Plasmid DNA was purified using silica spin columns (Epoch Life Sciences)
and the manufacturer recommended buffers. Standard molecular biology
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protocols were followed to clone sequences of interest into modified pCDFduet or
pETduet vectors for expression in E. coli or pBAD for expression in S.
typhimurium. Restriction enzymes and Quick Ligase (New England Biolabs) were
used as per manufacturer specifications. E. coli were rendered chemically
competent for transformation with DNA by growing cells to an OD600 of 0.3 and
washing cells 4 times with 10 mM tris.Cl pH=7.0, 60 mM CaCl2 in 15% glycerol,
85% water at 4°C and snap freezing cells in liquid nitrogen. Cells were thawed
and incubated with DNA for 0.5 h on ice, heat shocked at 42°C for 60 s,
recovered on ice for 2-5 minutes, and then grown in LB (formulation below) for 1
h at 37°C prior to plating on LB agar with antibiotic selection.
LB broth (Miller formulation: 1% w/v tryptone, 0.5% w/v yeast extract, 1%
w/v NaCl; Boston BioProducts) or LB agar (Lenox formulation: 1% w/v tryptone,
0.5% w/v yeast extract, 0.5% w/v NaCl 1.5% w/v agar; Boston BioProducts) were
used to culture bacteria unless otherwise specified. Antibiotics were used a the
following concentrations: ampicillin, 100 µg/mL; streptomycin, 10 0µg/mL;
kanamycin, 50µg/mL; tetracycline, 10 µg/mL.
S. typhimurium genomic mutants were produced using homologous
recombination from SacB-expressing suicide plasmids (36). SM10λpir E. coli
were used to carry suicide plasmids and deliver them to S. typhimurium by
conjugation. Plasmid carrying SM10λpir (tetracycline resistant) and target
Salmonella (streptomycin resistant) were grown overnight on LB agar plates,
resuspended in LB broth, and pelleted by centrifugation for 5 minutes at 2300 g.
The E. coli and Salmonella were resuspended together in 50-75 µL LB broth,
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spotted to antibiotic-free LB agar plates, incubated at 37°C overnight, and spread
on LB agar containing streptomycin and tetracycline. Exconjugates were
restreaked on the same media. Individual colonies were picked and grown for 2 h
in 1 mL LB with streptomycin and tetracycline, diluted 100-fold into a fresh 1 mL
LB containing only streptomycin, grown for 2 h, and 1-10 µL were plated to Lagar plates (1% w/v tryptone, 0.5% w/v yeast extract, 0.05% w/v NaCl, 1.5%
agar) supplemented with 10% w/v sucrose and grown overnight at 30°C. Double
recombinants were confirmed by PCR and tetracycline sensitivity. All spaO and
orgB mutants were prepared on the SB1741 background. fliM and fliN mutants
were prepared on the SB300 background.
S. typhimurium were rendered electrocompetent for transformation with
DNA by growing cells to an OD600 of 0.3 and then washing 4 times with 10%
glycerol at 4°C. Cells were incubated with salt-free DNA for 5 minutes before
electroporation in 0.2 cm cuvettes with a Bio-Rad MicroPulser using the
preprogrammed settings for gram-negative bacteria. Cells were recovered at
37°C for 1 h prior to plating on LB agar with selective antibiotics.
Bacterial strains carrying plasmids (Table 7.1) or genomic modifications
(Table 7.2) were stored by diluting an aliquot of overnight culture in LB 1:1 with a
solution of 65% glycerol, 20 mM tris.Cl pH=8.0, 100 mM MgCl2 and frozen at
-80°C.
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Table 7.1: Plasmids used in this study. Listed in order of appearance in the
figures.
Plasmid ID

E. coli Strain

Description

1366 BL21DE3Gold

12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet

7000 BL21DE3Gold

12HIS(3C)::SpaO(1-303, Val203GTT) in Stebbins modified
pCDF-Duet

3013 BL21DE3Gold

12HIS(3C)::SpaO(1-303, Val203GTT) in Stebbins modified
pCDF-Duet position 1. Position 2 contains SpaO(222-303).

3483 BL21DE3Gold

12HIS(3C)::SpaO(232-297) in Stebbins modified pCDF-Duet

3804 BL21DE3Gold

12HIS(3C)::SpaO(145-213) in Stebbins modified pCDF-Duet

3702 BL21DE3Gold

12HIS(3C)::SpaO(140-297, Val203GTT) in Stebbins modified
pCDF-Duet

5860 BL21DE3Gold

3xFLAG::SpaO(1-219) in pBAD

6044 BL21DE3Gold

3xFLAG::SpaO(1-303) in pBAD

6046 BL21DE3Gold

3xFLAG::SpaO(1-303, stop after codon 140) in pBAD

5862 BL21DE3Gold

3xFLAG::SpaO(140-303) in pBAD

5213 BL21DE3Gold

3xFLAG::SpaO(204-303) in pBAD

5977 SM10λpir

Suicide plasmid for spaO(∆1-202)

5973 SM10λpir

Suicide plasmid for spaO(∆1-139)

5976 SM10λpir

Suicide plasmid for spaO(Stop after codon 140)

5983 SM10λpir

Suicide plasmid for spaO(double stop after codon 219)

5858 BL21DE3Gold

InvC (untagged) in modified pET-Duet

5412 BL21DE3Gold

12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet
position 1. OrgB is in position 2.

3796 BL21DE3Gold

12HIS(3C)::SpaO(140-297, Val203GTT) in Stebbins modified
pCDF-Duet position 1. OrgB is in position 2.

1658 BL21DE3Gold

12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet
position 1. OrgA is in position 2.

1835 BL21DE3Gold

12HIS(3C)::InvC in modified pET-Duet position 1. OrgB is in
position 2.

1917 BL21DE3Gold

SpaO(1-303) (untagged) in modified pCDF-Duet position 1,
SpaO(203-303) in position 2.
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Table 7.1: Plasmids used in this study (continued).
Plasmid ID

E. coli Strain

Description

1930 BL21DE3Gold

OrgA (untagged) in modified pCOLA-Duet position 1,
SpaO(203-303) in position 2.

3006 BL21DE3Gold

12HIS(3C)::OrgA in Stebbins lab modified pCDF-Duet position
1, SpaO(203-303) in position 2.

3599 BL21DE3Gold

12HIS(3C)::InvC in modified pET-Duet position 1.
OrgB(31-226) is in position 2.

3474 BL21DE3Gold

12HIS(3C)::Thioredoxin(3C)::OrgB(2-30) in Stebbins modified
pCDF-Duet

5180 BL21DE3Gold

OrgB(1-30)::T4 lysozyme::6HIS in modified pCDF-Duet

3848 BL21DE3Gold

12HIS(3C)::OrgB(1-30)::T4 lysozyme in Stebbins modified
pCDF-Duet

5631 BL21DE3Gold

12HIS(3C)::OrgB(1-30)::Cerulean in Stebbins modified pCDFDuet

3648 BL21DE3Gold

12HIS(3C)::OrgB(1-70) in Stebbins modified pCDF-Duet

5873 BL21DE3Gold

12HIS(3C)::SpaO(1-303) in Stebbins modified pCDF-Duet
position 1. OrgB (I17D, L18D, I19D) is in position 2.

5868 BL21DE3Gold

12HIS(3C)::InvC in modified pET-Duet position 1. OrgB (I17D,
L18D, I19D) is in position 2.

5946 SM10λpir

Suicide plasmid for orgB(I17D, L18D, I19D)

5392 SM10λpir

Suicide plasmid for EGFP::3xFLAG::spaO

5102 BL21DE3Gold

12HIS(3C)::InvA(316-686) in Stebbins modified pCDF-Duet

5152 BL21DE3Gold

FliH(1-43)::T4 lysozyme::6HIS

5178 BL21DE3Gold

SsaK(1-32)::T4 lysozyme::6HIS

3987 BL21DE3Gold

12HIS(3C)::FliM(245-320) in Stebbins modified pCDF-Duet
position 1. FliN(1-137) is in position 2.

5968 BL21DE3Gold

12HIS(3C)::FliN(1-137) in Stebbins modified pCDF-Duet

5032 SM10λpir

Suicide plasmid for ∆fliMN

5962 SM10λpir

Suicide plasmid for fliM::fliN(5-137)

5100 BL21DE3Gold

12HIS(3C)::FliM(245-334)::FliN(5-137) in Stebbins modified
pCDF-Duet

3879 BL21DE3Gold

12HIS(3C)::FliH(1-43)::T4 lysozyme in Stebbins modified
pCDF-Duet
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Table 7.1: Plasmids used in this study (continued).
Plasmid ID

E. coli Strain

Description

5449 BL21DE3Gold

12HIS(3C)::FliH(1-18)::T4 lysozyme in Stebbins modified
pCDF-Duet

4086 BL21DE3Gold

12HIS(3C)::SpaO(1-142)::T4 lysozyme in Stebbins modified
pCDF-Duet

3675 BL21DE3Gold

12HIS(3C)::SpaO(1-140) in Stebbins modified pCDF-Duet

5671 BL21DE3Gold

12HIS(3C)::SpaO(115-297)::Venus in Stebbins modified pCDFDuet
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Table 7.2: S. typhimurium strains used in this study. Listed in order of
appearance in the figures.
Strain ID

Description

SB300 Wild-type. Gift of J. Gálan.
SB1741 3xFLAG::spaO. Gift of J. Gálan.
SB2130 ∆spaO. Gift of J. Gálan.
5161 3xFLAG::spaO(∆1-202)
6011 5161 carrying plasmid 5860
6033 SB2130 carrying plasmid 5860
6008 3xFLAG::spaO(double stop after codon 219)
5995 3xFLAG::spaO(∆1-139)
5999 3xFLAG::spaO(stop after codon 140)
6036 SB2130 carrying plasmid 5213
6035 SB2130 carrying plasmid 5862
6054 SB2130 carrying plasmid 6044
6056 SB2130 carrying plasmid 6046
SB2136 3xFLAG::spaO, ∆orgB. Gift of J. Gálan.
5683 3xFLAG::spaO, orgB(I17D, L18D, I19D)
5965 EGFP::3xFLAG::spaO
5958 EGFP::3xFLAG::spaO, ∆orgB
5925 EGFP::3xFLAG::spaO, orgB(I17D, L18D, I19D)
5057 ∆fliMN
5993 fliM::fliN(5-137)
6061 5995 carrying plasmid 6044
6062 5995 carrying plasmid 6046

142

7.3 Protein expression and purification
Constructs were transformed into BL21(DE3)Gold E. coli for heterologous
expression and protein expression induced mostly as described (197).
Specifically, bacteria were grown to an OD600 of 0.5-0.6 at 37°C in LB medium,
the cultures were cooled to 18°C, induced with 250 µM IPTG, and grown
overnight at 18°C. Selenomethionine (SeMet) substituted protein was produced
in the methionine auxotrophic E. coli B834(DE3) grown in methionine-free media
supplemented with SeMet (197). Uniformly labeled 15N/13C- or 2H/15N/13C- protein
samples were produced by overexpression in isotopically enriched minimal
media. Deuterium oxide, 15N-ammonium chloride, and 13C-glucose were obtained
from Cambridge Isotope Labs.
After induction overnight at 18°C, cells were harvested by centrifugation
and resuspended in lysis buffer (200 mM NaCl, 20 mM Tris(hydroxymethyl)aminomethane (tris).Cl pH=8.0, 5% v/v glycerol, 3 mM imidazole.Cl pH=8.0, 5
mM MgCl2, 5 mM 2-mercaptoethanol, 1 mM PMSF, and 0.1 mg/mL DNaseI).
Cells were lysed by 1-2 passes through a mechanical homogenizer (Avestin C5)
at 4°C.
Proteins were purified from E. coli cell lysates under native or denaturing
conditions (as indicated for each downstream application below) and affinity
purified on NiNTA agarose resin (Qiagen). For purification under native
conditions, all steps were performed at 4°C. Lysate was clarified by centrifugation
for 0.5 h at 30,000 g and loaded onto NiNTA resin by gravity flow. The column
was washed with 5-10 volumes of wash buffer (200 mM NaCl, 20 mM tris.Cl
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pH=8.0, 5%v/v glycerol, 30 mM imidazole.Cl pH=8.0) and then eluted in elution
buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5%v/v glycerol, 360 mM
imidazole.Cl pH=8.0). The elution was supplemented with 1 mM EDTA and
dialyzed overnight against 200 mM NaCl, 20 mM tris.Cl pH=8.0, 1 mM
dithiothreitol. Affinity tags were removed by cleavage with HRV 3C protease.
For purification under denaturing conditions, guanidinium chloride was
added to the lysate to a final concentration of 6 M. The post extraction lystate
was clarified by centrifugation at 30,000 g for 0.25 h at 4°C and loaded onto
NiNTA resin in batch at 25°C. Still at 25°C, the resin was washed with denaturing
wash buffer (8 M urea, 500 mM NaCl, 20 mM tris.Cl pH=8.0, 30 mM imidazole.Cl
pH=8.0) and eluted in denaturing elution buffer (8 M urea, 200 mM NaCl, 20 mM
tris.Cl pH=8.0, 360 mM imidazole.Cl pH=8.0). Urea containing solutions were
stabilized by the addition of 75 mM ammonium sulfate. The elution was
supplemented with 5 mM EDTA and 5 mM DTT and protein refolded by dialysis
against 200 mM NaCl, 20 mM tris.Cl pH=8.0, 1 mM DTT (3-4 changes, dialysis
time of 24 h total, 4°C). For T4 lysozyme fusions, 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES).Na pH=7.0 was substituted for tris.Cl
pH=8.0. Insoluble material was removed by centrifugation or filtration and affinity
tags were removed by cleavage with HRV 3C protease.
Affinity purified proteins were further purified by ion exchange
chromatography using an AKTA FPLC and the following columns (GE
Healthcare): T4 lysozyme fusions were purified by cation exchange on a
SourceS column; all other constructs were purified by anion exchange on a
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SourceQ column. For cation exchange chromatography, proteins were loaded in
batch in 10 mM HEPES.Na pH=7.0, 50-100 mM NaCl and eluted by a NaCl
gradient (from 0 to 1000 mM) in the same buffer. For anion exchange, proteins
were loaded in batch in 20 mM tris.Cl pH=8.0, 50-100 mM NaCl and eluted by a
NaCl gradient (from 0 to 1000 mM) in the same buffer.
Prior to crystallography, ion exchange purified proteins were further
purified by gel filtration chromatography on a Superdex 75 column (GE
Healthcare) in final buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 2 mM DTT) and
concentrated using centrifugal concentrators (Amicon). To form the SpaOOrgB::lysozyme complex for crystallization, cation exchange purified
OrgB(1-30)::T4 lysozyme was mixed with an excess of anion exchange purified
SpaO(145-213) + SpaO(232-297) and allowed to incubate overnight at 4°C. The
SpaO-OrgB::lysozyme complex was then purified by gel filtration
chromatography. To form the FliM::FliN-FliH::lysozyme complex for
crystallization, anion exchange purified FliM(245-334)::FliN(5-137) was mixed
with an excess of cation exchange purified FliH(1-18)::T4 lysozyme and allowed
to incubate overnight at 4°C. The FliM::FliN-FliH::lysozyme complex was then
purified by gel filtration chromatography.
Protein samples were analyzed by SDS-PAGE on 15% polyacrylamide
gels. Samples were run in Laemmli running buffer (192 mM glycine, 25 mM tris,
0.1% w/v SDS) unless a component of interest was less than 15 kDa, in which
case tris-tricine running buffer was used instead (100 mM tris, 100 mM tricine,
0.1% w/v SDS). Gels were stained with coomassie (2 mg/mL coomassie dye in
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50% methanol, 40% water, 10% acetic acid) and destained in 30% methanol,
60% water, 10% acetic acid).

7.4 Crystallization
All proteins were crystallized by hanging drop vapor diffusion with 1:1 and 2:1
ratios of protein (in final buffer) to precipitant at 25°C (except where noted). For
crystallization, SpaO(232-297) and FliM(245-334)::FliN(5-137) were purified
under native conditions; SpaO(145-213) and SpaO(232-297) were purified under
denaturing conditions and co-refolded; the T4 lysozyme fusions were purified
under denaturing conditions, refolded, and mixed with their cognate SPOA1SPOA2 as described above. The protein concentrations, crystallization buffers,
and cryoprotection conditions for each protein or complex are as follows:
SpaO(232-297) was concentrated to 8 mg/mL and crystallized with 35%
PEG400, 200 mM calcium acetate, 100 mM sodium acetate pH=5.0. Crystals
were cryoprotected in the mother liquor. Microseeding was employed to enhance
crystal uniformity and diffraction. Briefly, crystals to be seeded were harvested in
precipitant solution and vortexed in a microfuge tube with a small stir bar for ~60
s. The slurry of microseeds was serially dilluted (5-10-fold steps) in precipitant
solution and 5 selected microseed-precipitant mixtures were mixed with fresh
protein as in a normal hanging drop experiment.
SpaO(145-213) + SpaO(232-297) was concentrated to 12 mg/mL and
crystallized with 25% PEG400, 10% isopropanol, 100 mM sodium citrate pH=5.6
at 4°C. Microseeding (as above) was employed to enhance crystal uniformity and
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diffraction. Crystals were cryoprotected in mother liquor with the PEG400
concentration raised to 37.5%.
SpaO(145-213) + SpaO(232-297) + OrgB(1-30)::T4 lysozyme was
concentrated to 18.5 mg/mL and crystallized with 25% PEG3350, 200 mM
ammonium formate, 100 mM sodium acetate pH=5.0. Microseeding (as above)
was employed to enhance crystal uniformity and diffraction. Crystals were
cryoprotected in 30% PEG3350, 10% glycerol, 200 mM ammonium acetate, 100
mM sodium acetate pH=5.0.
SpaO(145-213, SeMet) + SpaO(232-297, SeMet) + OrgB(1-30)::T4
lysozyme (native) was concentrated to 18 mg/mL, supplemented with 50 mM
maltose, and crystallized with 25% PEG3350, 200 mM ammonium formate, 100
mM sodium acetate pH=5.0. Microseeding (as above) was employed to enhance
crystal uniformity and diffraction. Crystals were cryoprotected in 25% PEG3350,
10% ethylene glycol, 200 mM ammonium formate, 100 mM sodium acetate
pH=5.0, 50 mM maltose.
FliM(245-334)::FliN(5-137) was concentrated to 7.5 mg/mL and
crystallized with 2.2 M NaCl, 100 mM imidazole.Cl pH=8.0. Crystals were
cryoprotected with 2 M NaCl, 100 mM imidazole.Cl pH=8.0, 30% glycerol.
FliM(245-334)::FliN(5-137) + FliH(1-18)::T4 lysozyme was concentrated to
17 mg/mL and crystallized with 11% PEG400, 100 mM sodium potassium
phosphate pH=6.5. Crystals were cryoprotected with 40% PEG400, 200 mM
sodium potassium phosphate pH=6.5.
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7.5 Structure determination
Data were collected at the National Synchrotron Light Source (Brookhaven
National Laboratory) beamline X29A at a temperature of -173°C using the
following X-ray wavelengths: 0.979 Å for SeMet crystals, 1.075 Å for native
crystals. Diffraction data sets were indexed and integrated in iMOSFLM (198)
and scaled and reduced with AIMLESS (199). Data sets were truncated at I/
σI>2.0, and all sets were determined to have a CC1/2>0.7 in the outermost
resolution shell (200).
The PHENIX program suite (201) was used to solve the crystallographic
phase problem. SpaO(232-297), SpaO(145-213) + SpaO(232-297), and
FliM(245-334)::FliN(5-137) were solved by SeMet single wavelength anomalous
diffraction in Autosol. The SPOA1-SPOA2-APAR::lysozyme structures were
solved by molecular replacement in Phaser-MR using the experimentally phased
cognate SPOA1-SPOA2 structure and T4 lysozyme (PDB 2LZM). Structures
were built in Phenix (Autobuild) with additional manual model building performed
in Coot (202). Structures were refined and validated in Phenix. SpaO(145-213) +
SpaO(232-297) + OrgB(1-30)::T4 lysozyme crystals exhibited twinning and were
refined in Phenix using the twin law l,-k,h. ANODE (186) was used to perform
post-hoc analysis of anomalous scatters in SpaO(145-213, SeMet) + SpaO
(232-297, SeMet) + OrgB(1-30)::T4 lysozyme crystals, providing additional
empirical support for the SpaO-OrgB model coordinates. Except where indicated,
all representations of models and maps for figures were produced in QtMG (203).
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7.6 NMR spectroscopy
The NMR sample of refolded SpaO(140-297) consisted of 0.3 mM U-2H/15N/13C
labeled protein in 10 mM citrate buffer at pH 5.6 with 90%H2O/10%D2O (v/v),
100 mM NaCl, and 1 mM dithiothreitol. For comparison of the apo and APARbound forms,

15N/13C-labeled

SpaO(140-297) was co-refolded with an excess of

unlabeled thioredoxin::OrgB(2-30). The thioredoxin solublization tag was cleaved
off by overnight incubation with HRV 3C protease. Protease and affinity tags
were removed on NiNTA resin and the SpaO-OrgB complex was separated from
the majority of free thioredoxin by Superdex75 gel filtration chromatography. The
final concentration of the protein complex was 0.2 mM in 10 mM citrate buffer at
pH 5.6 supplemented with 10% v/v deuterium oxide, 100 mM NaCl, and 2 mM
dithiothreitol.
The NMR data were collected on Bruker 600, 800, and 900 MHz AVANCE
spectrometers equipped with TCI/TXI CryoProbes™ at 20°C for the apo-SpaO
and 30°C for the APAR-bound forms. For resonance assignments of apo-SpaO,
transverse relaxation optimized (TROSY) triple resonance (204) experiments
including trHNCO, trHN(CA)CO, trHNCA, trHN(CO)CA, trHNCACB and
trHN(CO)CACB were acquired at 600 and 900 MHz. A

15N-NOESY-HSQC

spectrum with 100 ms mixing time was also acquired at 900 MHz. To assign
APAR-bound SpaO, a suite of conventional backbone experiments (205) were
acquired at 600 and 800 MHz.
The data were processed in Topspin 2.1 spectra and analyzed using the
Autolink module in CARA 1.5 (206). The heteronuclear chemical shifts were
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analyzed using the TALOS+ (181) database to predict the secondary structure of
the protein. The weighted CSD were calculated from amide proton (δH) and
nitrogen chemical shifts (δ15N) using the following equation:
CSD = (∆ δ H)2 +(

∆ δ 15 N 2
)
5

7.7 Co-affinity purification assays
For co-affinity purification of the SpaO-OrgB-InvC complex (Figures 3.1, 3.2, and
3.3), the proteins indicated were co-expressed and purified under native
conditions as described above.
For the SPOA-APAR::lysozyme pulldown experiment (Figure 4.2), the
indicated SPOA-containing proteins were Ni-affinity purified under native
conditions, their affinity tags removed by overnight incubation with HRV protease
3C, and they were further purified by anion exchange chromatography (as
above). APAR::lysozyme fusions were separately purified under denaturing
conditions and were subjected to cation exchange chromatography after
refolding (as above). 1 mg of hexahistidine-tagged APAR::lysozyme fusion
protein was mixed with 2 mg of the indicated SPOA-containing protein in 0.2 M
NaCl, 20 mM tris.Cl pH=8.0 (final volume 4 mL) and incubated on ice for 2 h. The
mixture was twice passed over 2 mL of NiNTA resin, washed with 8 mL wash
buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5% v/v glycerol, 30 mM imidazole.Cl
pH=8.0) and then eluted in 3.5 mL elution buffer (200 mM NaCl, 20 mM tris.Cl
pH=8.0, 5% v/v glycerol, 360 mM imidazole.Cl pH=8.0). For Figure 3.4, the same

150

procedure was followed but glycerol was excluded from the wash and elution
buffers, and 2 x 5 mL washes were used instead of 1 x 8 mL, which reduced
background binding.
For the InvA-APAR binding experiment (Figure 3.14), all proteins were
purified under native conditions, the OrgB(1-30)::Cerulean fusion was cleaved
from its affinity tag with 3C protease, and the proteins were further purified by
anion exchange chromatography (as above). 125 µM OrgB(1-30)::Cerulean was
mixed with 125 µM double hexahistidine-tagged InvA(316-686) or
SpaO(140-297) in a final volume of 1 mL (0.2 M NaCl, 20 mM tris.Cl pH=8.0, 5
mM β-mercaptoethanol). After 4 h on ice, mixtures were passed over 1 mL NiNTA
resin, washed with 6 mL of wash buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5%
v/v glycerol, 30 mM imidazole.Cl pH=8.0) and then eluted in 4 mL of elution
buffer (200 mM NaCl, 20 mM tris.Cl pH=8.0, 5% v/v glycerol, 360 mM
imidazole.Cl pH=8.0).
For the SPOA2-NTD binding experiment (Figure 5.1), double
hexahistidine-tagged SpaO(232-297) was purified under native conditions and
anion exchange purified without removal of the affinity tags. SpaO(1-142)::T4
lysozyme was purified under denaturing conditions, refolded, affinity tags
removed with 3C protease, and further purified by cation exchange
chromatography. 1 mg of double hexahistidine-tagged SpaO(232-297) was
mixed with 2 mg of SpaO(1-142)::T4 lysozyme in a total volume of 4 mL buffer
(0.2 M NaCl, 20 mM tris.Cl pH 7.0). After 2 h on ice, mixtures were passed over
1.5 mL NiNTA resin, washed with 8 mL of wash buffer (200 mM NaCl, 20 mM
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tris.Cl pH=7.0, 30 mM imidazole.Cl pH=7.0), washed again with 5 mL wash buffer
and then eluted in 4 mL of elution buffer (200 mM NaCl, 20 mM tris.Cl pH=7.0,
360 mM imidazole.Cl pH=7.0).

7.8 Isothermal titration calorimetry
Natively purified, 3C-cleaved SpaO(140-297), SpaO(232-297), or
OrgB(1-30)::Cerulean were anion exchange purified as described above.
SpaO(1-142)::T4 lysozyme was purified under denaturing conditions, refolded,
cleaved with 3C protease, and cation exchange purified as described above for
APAR::T4 lysozyme fusions. For the experiments in Figure 3.12, proteins were
dialyzed overnight against 0.2 M NaCl, 20 mM tris.Cl pH=8.0, 5 mM βmercaptoethanol. SpaO constructs were concentrated to 1 mM and injected into
100 µM OrgB(1-30)::Cerulean (or buffer for background subtraction). For the
experiments in Figure 5.2, proteins were dialyzed overnight against 150 mM
NaCl, 10 mM HEPES.Na pH=7.0, 5 mM β-mercaptoethanol. SpaO(232-297)
concentrated to 1 mM (dimer concentration) was injected into 100 µM
SpaO(1-142)::T4 lysozyme or SpaO(140-297) (or buffer for background
subtraction). All experiments were performed using an auto-ITC200 (GE
Healthcare) and data were processed in Origin. Values reported in the text are
the mean of 3 technical replicates ± standard deviation.
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7.9 In vitro secretion assay
S. typhimurium of the indicated genotype were grown for 6 h at 37°C in LB
medium with NaCl supplemented to a final concentration of 0.3 M. Cells were
pelleted by centrifugation at 3400 g for 0.5-1 h and the supernatants were 0.22
µm filtered. Secreted proteins were precipitated from the filtered supernatants
with 15% trichloroacetic acid overnight at 4°C. The precipitate was pelleted by
centrifugation at 3400 g for 1 h at 4°C, resuspended in ice cold acetone and
transferred to a microfuge tube. After 0.25 h on ice, the precipitate was harvested
by centrifugation at 16,000 g for 0.75 h at 4°C and resuspended in 0.2 M tris.Cl
pH=8.0, 0.2 M NaCl to neutralize any residual acid before the addition of SDSPAGE loading buffer. For plasmid complementation analysis, S. typhimurium
were electroporated with SpaO sequences cloned into the pBAD vector and
expression was induced with 0.01% arabinose for the entire duration of the
experiment.

7.10 Fluorescence microscopy
S. typhimurium were grown as for the in vitro secretion assay. Cells were
harvested by centrifugation, washed 3 times in PBS, and fixed overnight with 4%
formaldehyde in PBS at 4°C. Cells were again washed 3 times in PBS,
counterstained with DAPI (Sigma Aldrich) and/or 10 mM Nile Red (SigmaAldrich), and immobilized on poly-L-lysine (P4707, Sigma Aldrich) coated
coverslips.

[Poly-L-lysine coating: Coverslips were incubated with 400 µL of

0.01% poly-L-lysine for 1-2 h at room temperature, washed by immersion in
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distilled water (rapidly, five times) and air dried.] Covers were mounted in Prolong
Diamond (Life Technologies) and sealed with nail polish. Slides were imaged on
a DeltaVision Image Restoration Microscope with a 100x objective (Applied
Precision). Images were deconvoluted in Softworx (Applied Precision) and
processed identically in ImageJ (NIH) and Photoshop (Adobe).

7.11 Western blotting
After SDS-PAGE, samples were transferred to nitrocellulose membranes
(Amersham Hybond ECL) by electrophoresis overnight with a constant 60 mA
current in tris-glycine transfer buffer (20 mM tris, 150 mM glycine in 20%
methanol, 80% water). Blots were blocked at room temperature for 1h in TBST
(20 mM tris.Cl pH=7.4, 400 mM NaCl, 0.2% v/v Tween-20) supplemented with
5% w/v nonfat milk powder. Blots were incubated with primary antibody (mouse
anti-FLAG M2, Sigma F1804, 1:2000) in TBST/5% milk for 4 h at room
temperature, washed with TBST four times, and then incubated with secondary
antibody (goat anti-mouse IgG conjugated to horseradish peroxidase, Sigma
A4416, 1:2000) in TBST/5% milk for 2 h at room temperature. Blots were again
washed four times in TBST and then developed using the ECL 2 Western Blotting
Substrate kit (Pierce) as per manufacturers guidelines. Chemiluminescence was
visualized on a LAS-3000 Intelligent Dark Box (Fuji).
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7.12 FRET
Fluorescence readings were performed on a Spectramax Gemini XS plate reader
(Molecular Devices). Samples were excited with 435 nm light and emission
measurements made at 540 nm (acceptor fluorescence) and 480 nm (donor
fluorescence). Relative FRET efficiency was calculated as:
EFRET =

IA
ID + IA

where IA is the fluorescence intensity of the Venus acceptor stimulated by the
Cerulean donor (ex: 435 nm, em: 540 nm), and ID is the fluorescence intensity of
the Cerulean donor stimulated at its own maximum excitation wavelength (ex:
435 nm, em: 480 nm). FRET efficiency was scaled so that the background FRET
of an equimolar mixture of Cerulean and Venus (“C+V”) was set to 0:
Escaled =

Esample
−1
EC+V

A positive FRET control comprised of Cerulean fused to Venus with a 5 amino
acid linker (207) was obtained on plasmid (Addgene #26394).
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